Podcasts about PIL

Si è tenuta oggi a Milano la conferenza stampa che anticipa i dati del Paper realizzato da The European House-Ambrosetti per ADM - Associazione Distribuzione Moderna, dal titolo "L'Italia di oggi e di domani: il ruolo sociale ed economico della distribuzione moderna". I dati presentati dimostrano la distribuzione come argine all'inflazione, impulso al fatturato della filiera agroalimentare, occupazione e sostegno al PIL. Quello che emerge dallo studio è che nel 2022 le aziende della distribuzione moderna hanno assorbito 3,9 miliardi di euro di inflazione consentendo un risparmio fino a 77 euro al mese a famiglia. E che per le famiglie meno abbienti la variazione dei prezzi del paniere medio pesa per un +17,5% rispetto a un anno fa, che scende fino a un +9,6% per le famiglie più abbienti, con una media nazionale dell'11,6%. Ne parliamo conValerio De Molli, Managing Partner & CEO di The European House - Ambrosetti.Big Tech in crisi Dall'inizio del 2021 fino alla chiusura dell'anno le società della Silicon Valley hanno registrato licenziamenti per oltre 150.000 persone. Le Big Tech, da Alphabet-Google a Apple passando da Netflix, Amazon, Meta e Microsoft, nell'ultimo anno hanno perso oltre tremila miliardi di dollari di valore di mercato nell'ultimo anno. Ciononostante questi grandi gruppi hanno creato molti più posti di lavoro negli ultimi anni di quanti non ne distruggano adesso. E anche dopo un 2022 molto negativo, i colossi tecnologici hanno comunque generato oltre cinquemila miliardi di dollari di valore di Borsa in circa dieci anni. Ma è indubbio che la loro crescita esponenziale sempre essersi fermata. Approfondiamo il tema con l'appuntamento settimanale con "Dietro la notizia", la rubrica di Alessandro Plateroti, direttore di Notizie.it.Tim, il segnale di Vivendi: dimissioni di De Puyfontaine dal CdaDimissioni dal Cda Tim di Arnaud de Puyfontaine. Come anticipato sul sito del Sole 24 Ore il ceo di Vivendi e consigliere d'amministrazione di Telecom Italia dal 2015 ha rassegnato le sue dimissioni «irrevocabili» dal board della società di cui la media company francese è primo azionista con il 23,75%. La decisione sarebbe stata presa a valle di una riunione stamattina, nella mattinata di lunedì 16 gennaio, a Parigi.Il titolo Telecom Italia, intanto, sale dello 0,8% a metà mattinata, poi accelera oltre il 3% a 0,26 euro a Piazza Affari per 5,4 miliardi di capitalizzazione. La borsa, infatti, considera la mossa un segnale in vista della riunione del Consiglio d'amministrazione previsto per il prossimo 18 gennaio 2023. De Puyfontaine ha confermato che «Tim e l Italia restano centrali nei piani di investimento di Vivendi», le dimissioni potrebbero essere un endorsement nei confronti del Governo. Ne parliamo con Andrea Biondi de il Sole 24 Ore.

Will and Jason discuss the latest releases by Ribbon Stage and Green/Blue, plus deaths of the week and bonus songs.

ImmaLetYouFinish... #124 finds Court & Amy telling Harry to sit down, debating the importance of a Tuesday and defending PiL. ImmaLetYouFinish... is a proud member of Pantheon Podcasts.

Dans quels nouveaux films disponibles sur les plateformes peut-on voir l'incroyable acteur-caméléon ? Dans quel nouveau défi s'est lancé John Lydon, le punk légendaire des « Sex Pistols », chanteur de PIL ? Depuis combien d'années on n'avait plus entendu un nouveau titre de « Everything but the girl » ? La série « Copenhagen Cowboy », un retour gagnant pour Nicolas Winding Refn, le réalisateur de « Drive » ? Quoi de neuf en Flandres… Peut-être «The haunted youth » ? Des questions… Et des réponses dans « La semaine des 5 heures » de ce mercredi 11 janvier.

Values. Goals. Meaning. It's all part of the word cloud about ‘purpose' that Anna and Bonnie are making to start off the new year. They talk a little about a lot of stuff, including how existential philosophy and Viktor Frankl's logotherapy can help put our life meanings into perspective. Bonnie also gives Anna the Purpose in Life (PIL) test to see if Anna is in an existential void. So pop some champagne and settle in because the girls are back, baby! If you would like to take the PIL test yourself and read a little more about logotherapy, check that out here: https://exploringyourmind.com/evaluating-your-purpose-in-life-the-pil-test/

V médiích dlouhodobě komentuje dění na Ukrajině a na Ukrajinu také pravidelně vozí pomoc. V Praze působí coby redaktorka Ukrajinského žurnálu, organizuje Týden ukrajinského filmu a své vynikající znalosti ukrajinštiny, kterou se začala učit ve třech letech, využívá mimo jiné k titulkování snímků v záludných nářečích. „Ve filmu se setkává barva, zvuk, atmosféra. O zemi tak poví daleko víc než analytika nebo text,“ řekla ve Vizitce Tomáši Pilátovi.Všechny díly podcastu Vizitka můžete pohodlně poslouchat v mobilní aplikaci mujRozhlas pro Android a iOS nebo na webu mujRozhlas.cz.

L'approfondimento settimanale di Radio 24 dedicato al mondo dei trasporti e della logistica, un settore che rappresenta in Italia la terza filiera per fatturato (dopo l'agroalimentare e l'edilizia) e che vale il 12% del Pil nazionale, oltre a rappresentare la cerniera di collegamento tra il mondo produttivo e il consumatore finale. L'efficienza del sistema di trasporto, sia di passeggeri sia di merci, ha sempre avuto un ruolo determinante nello sviluppo economico e sociale di un popolo. E la capacità di muovere gli atomi -unita oggi a quella di spostare bit- può ancora cambiare le sorti di una nazione. La trasmissione è realizzata in collaborazione con il Comitato Centrale dell'Albo degli Autotrasportatori (Ministero delle infrastrutture e della mobilità sostenibili)

Programmets gæst i 2022 udgav sit debutalbum ”Kom Vi flyver, Siger du”, hun havde sine første headliner-koncerter i maj. Hun blev nomineret til en DMA i kategorien Årets nye danske navn. Gæsten er musikeren Pil. I anledning af at hun er ude med sin første single i 2023 gæster hun AFTENKLUBBEN til en snak om musik, ensomhed og actionfilm. Vært og tilrettelægger: Daniel Cesar.

A version of this essay was published by thepamphlet.in at https://www.thepamphlet.in/en/shadow-warrior-a-deplorable-supreme-court-decision-on-demonetization/The Supreme Court, in a 4:1 judgment, held that the 2016 Demonetization was acceptable. The dissenting judge, well, dissented, saying that it was flawed. This decision sets an awful precedent that will come back to haunt us all, and the judiciary is respectful of precedent. The law of unintended consequences will strike.It is not that demonetization per se was a bad idea, or that it was executed poorly, or that its goals were not met. It was a pretty good idea, it was executed moderately well, and the declared goals, to reduce corruption, terror funding through counterfeit notes, and to increase the proportion of ‘white' money in circulation, were met to an extent. No, the problem is twofold: one, an unprecedented and unwarranted level of judicial overreach and encroachment into the domain of the Executive; two, the common sense principle of fait accompli: this is a done deal, and it is essentially impossible to undo it. The point is that the judiciary has its role, which is in hair-splitting legal jargon and in particular the verbiage of the Constitution. With all due respect, judges are not trained in other disciplines, and would be hard-pressed to understand economics, or engineering, or medicine, or military affairs. They simply will not be able to make judicious decisions (to give them credit, the majority opinion did concede this). But then, they should not take up such cases in the first place. I can imagine motivated petitioners waiting in the wings to now ask the Supreme Court to undo the 1971 Bangladesh War, the decision to impose covid-related mandates, or the Mangalyaan space probe. In fact, you could find somebody to make a cogent argument that the Constitution should not have been accepted in 1950, and that it should be rolled back. There is no end to such litigation, and if it is allowed to proliferate, it would clog up the entire judiciary. Of course, the entire judiciary is already clogged up with 30 million cases, so why open the flood-gates and invite more frivolous litigation?As for the law of unintended consequences, there is the recent experience of the Democrats in the US. After years of claiming ex-President Trump's tax returns would reveal deep, dark secrets, they forced him to reveal them: and it was a damp squib, with nothing of significance, no tax evasion. But the precedent has been set, and the Republicans will now use this to harass every Democrat alleging skeletons in their tax closets. The Indian Supreme Court should stick to its fundamental task: interpreting the Constitution. Not being a lawyer, I cannot say authoritatively that there is no constitutional issue in the anti-demonetization lawsuit, but I doubt it. It is a purely administrative issue, and thus the domain of the Executive, just as making a multitude of daily decisions is. The activist Indian courts have long been accused of interfering in everything while at the same time creating cozy little fiefdoms for themselves, for instance in the continuous creation of post-retirement sinecures for judges, the most recent being the demand that retired judges should be on the committee choosing the Chief Election Commissioner.The most obvious example of bad faith is the judiciary's closed and opaque Collegium system, wherein they nominate and appoint themselves, with the predictable result of nepotism and hereditary elites. It is high time that Parliament put a stop to this, and created new laws that mandate a role for the Executive. The proposed NJAC could be one way forward. If the NJAC is unconstitutional, well then, bring in a constitutional amendment. Many people have talked about judicial reforms; I too took a stab at it a few years ago (“Can we fix the deeply troubled judiciary?” Swarajya, May 2018). One of my points was the radical restructuring of the system into a Supreme Court that only hears constitutional cases, and a new set of regional Courts of Appeal, with status almost equivalent to the Supreme Court, that hear other things beyond the ken of state High Courts. There is a serious concern about which cases the Supreme Court chooses to hear. At the moment, it appears whimsical. Why on earth would the SC hear cases about cricket, which is a mere entertainment? Why on earth would the SC not hear petitions about the 1990s ethnic cleansing of Kashmiri Hindus (it has refused to do so three times already).The terror onslaught in Jammu and Kashmir is not history. We saw with horror the terrorist attack on Hindus in Jammu's Rajouri just days ago, where the attackers reportedly identified Hindus by their Aadhar cards, and then shot them. This is an urgent, ongoing problem, and why does the court refuse to hear it, while at the same time accepting a case on the 1948 assassination of Mahatma Gandhi? Next, someone will file a PIL demanding the undoing of that assassination.Why does the SC accept PILs (Public Interest Litigations) put up by motivated NGOs, often with foreign funding? These people are able to get, through the back door, rapid decisions that affect the entire country, whereas the cases should properly be heard at the local level in District Courts, and only be elevated to the Supreme Court through a proper process if they actually have merit.Apart from this, some actions are virtually impossible to undo: time and tide wait for no man. How could the SC, like King Canute who ordered the waves to retreat, even possibly consider the undoing of demonetization? How will it be done? What about the major moves in digitization that resulted, the UPI revolution, the trillions of rupees flowing through a payment system that is now ubiquitous and available to anyone with a mobile phone?India has now become one of the most digitally connected countries in the world, but the amount of cash in the system is now even greater than at the time of demonetization. Can the court explain why? So it is not as though cash suddenly disappeared. Yes, there was a temporary crunch, and yes, it was hardship for many, but on average, most people have recovered.Malign NGOs have continually opposed national interests: remember Sterlite? Or the Sardar Sarovar dam? By accepting a plea that was clearly inappropriate, probably politically motivated, and in any case something that would be virtually impossible to undo, the Supreme Court has set a poor precedent. The Indian judiciary acts as a law unto itself, unaccountable to anybody else. This is wrong. As the President and the Vice President mentioned recently, it is time the judiciary reformed itself. I suspect it will have to be done forcibly, not voluntarily.1090 words, 3 Jan 2023 This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit rajeevsrinivasan.substack.com

Karagöz ve Hacivat Hacivat (Soldan girer.) Hacivat: Vay Karagözüm, canım efendim, devletlim, sultanım, günaydın! Karagöz : Hay, bostan kuyusunun dibinde kalaydın! Hacivat: Karagözüm, hayırlı sabahlar olsun! Karagöz : Leş kargaları iki gözünü oysun! (Vurur) Hacivat: Aman Karagözüm, bana niçin vurursun? Ben sana güzel, hayırlı sabahlar diledim. Karagöz : Hasta yatıyordum, kafamı ütüledin. Hacivat: Niyetim akıl danışmak, yenemediğim bir güçlüğü yenmekti. Gece uykularım kaçtı. Düşündüm taşındım... Diyorum ki, bir iş çevirelim seninle... Karagöz : Çeviririz. Ama çevirdiğimiz bütün işler, sonunda arap saçına döner. Hacivat: Hayır, dönmez gözümün elifi. Karagöz : Şeytan diyor, gırtlakla şu herifi! Hacivat : Çok düşündüm, kazın ayağı öyle değil bu sefer. Karagöz : Peki nasılmış? Çıkar ayakkabını göster! Hacivat : Karagözüm, gece aklıma gelen öyle bir iştir ki, Allah inandırsın, azıcık bir emekle küpünü dolduracak, paraya para demeyeceksin. Karagöz : Daha dırlanırsan, köteği yiyeceksin! (Vurur) Hacivat : Ben bu tokatları, girişeceğim işin hatırı için yiyorum, yoksa yemem. Karagöz : Kırk yıllık sansara kurnaz tilki diyemem. Hacivat : Karagözüm, sen hiç sinema bilir misin? Karagöz : Bilirim. Hacivat : Doğru söyle, hiç sinemaya gittin mi? Karagöz : Gittim. Hacivat : Nasıl bir yerdir? Karagöz : Karanlıktır. Hacivat : Tamam, bunu bildin. Peki, insan sinemaya niçin gider? Karagöz : En başta, elbette, gözünü gönlünü eğlendirmek için gider. Hacivat : Hisse kapmaz mı? Karagöz : Kapar. Hacivat : İbret dersi almaz mı? Karagöz : Alır. Hacivat : Peki, bir film çevirsek, o hisseyi, ibret dersini veremez miyiz? Karagöz : Veremeyiz. Hacivat : Niye? Karagöz : Sende tıraş çok, bende okuma yazma yok. Hacivat : Bak Karagözüm, biraz düşün; her filmin içine bunca çarşı pazarı neden koyarlar? Karagöz : Koyarlar ki Hacivat, bu ölümlü dünyanın ucunda pazar var, pazarlık var. Her şey uyuşmaya bakar. Hacivat : Bak, nazar değmesin, bu işin olacağına senin de aklın kesti. Şimdi sıra, "Hicran Yarası" adlı bu filmin prodüktörünü, rejisörünü, senaristini ve baş artistini bulmaya geldi. Karagöz : Saydıkların nedir? Anlayamadım. Hacivat : Çevrilecek filmin yapımcısı, çekim- cisi, yazıcısı, yönetmeni, baş oyuncusu. Sıra bunları bulmaya geldi. Karagöz : Saydıkların olmadan film çekilemez mi? Hacivat : Çekilemez. Karagöz : (Üzerine yürür) Sen şöyle uzak dur, ben çekerim. Hacivat : Çekemezsin. Karagöz : Pilâvdan dönenin tahta kaşığı kırılsın, çekerim. Hacivat : Karagöz, sen çıldırdın mı? Karagöz : Saydıklarının hepsi ben olacağım. Olamazsam, ya şu senin keçi sakalını, ya da şu benim top sakalımı yolacağım. Mehmet SEYDA

Shira Lazar is the founder and CEO of the Emmy Nominated digital media brand What's Trending. She is a Web3 advocate, collector, and advises as well as consults with companies focusing on culture and blockchain tech. As a broadcaster, Shira uses her platforms to create content and education around Web3, bridging the gap between the industry, creators, and consumers.  While in quarantine in April 2020, Shira launched PeaceInside.Live, a wellness community and platform offering classes, workshops, and retreats. PIL has worked with companies like Capital One, HBO, and Spotify. Since its launch, the company has expanded and now works with Web3 companies, communities, and teams building customized wellness programming that can be experienced both virtually and IRL. Listen to this Takin' Care of Lady Business episode with Shira Lazar about what's trending in Web 3, given all the crazy headlines, and how she's on a mission to put wellness at the forefront of it all. Here is what to expect on this week's show: How Shira's digital publishing company, What's Trending, has helped cover Web2 and Web3 and what has changed in Web3.  How women in Web3 are helping redefine success away from just financial success  How Shira's new company Peace Inside is helping incorporate wellness and avoid burnout in Web3  How finding her purpose and living her authentic truth led Shira to success Connect with Shira: Website: https://www.shiralazar.com | https://www.peaceinside.live/ LinkedIn:https://www.linkedin.com/in/shiralazar/ Facebook: https://www.facebook.com/ShiraLazar/ Instagram: @shiralazar Twitter: @shiralazar  Learn more about your ad choices. Visit megaphone.fm/adchoices

#180 2023 chegou tal qual anunciou Alceu, que tu virias numa manhã de domingo, peito nu, cabelo ao vento, feito surfista mesmo. Voltamos, Júlio, Bruno e João, prontos para mais 51 semanas de episódios fresquinhos e crocantes toda terça no seu tocador predileto - de graça! Nos despedimos do Rei Pelé, ouvimos o Tito com atenção, fizemos listas de canções sem sentido nenhum, apresentamos Almanaque e Imagem falada, desejamos aquele desajeitado feliz ano novo e voltamos ao batente. Por algum motivo que não sabemos explicar, estamos mais leves, o programa foi divertido e diversificado -ninguém leva (muito) a sério - um Boia como deve ser. As trilhas desfilaram de Jethro Tull até Nélson Angêlo, passando por PIL, Black Pumas, Michael Head, Fountaines DC e Prefab Sprout. Eu já escuto os teus sinais. --- Send in a voice message: https://anchor.fm/boia/message

Tentokrát přinese rozhovor s Marianem Fiedlerem, který aktivně pomáhá lidem a hlavně dětem na Ukrajině, představí Agátu Pilátovou, která se věnuje rusínské menšině a nedávno za to dostala cenu za celoživotní dílo a na závěr vás vezme na koncert jednoho z nejznámějších chorvatských klavíristů Lovra Pogoreliče v Praze. Pořad připravila Tajana Mančalová, moderuje Tomáš Pilát.

Tentokrát přinese rozhovor s Marianem Fiedlerem, který aktivně pomáhá lidem a hlavně dětem na Ukrajině, představí Agátu Pilátovou, která se věnuje rusínské menšině a nedávno za to dostala cenu za celoživotní dílo a na závěr vás vezme na koncert jednoho z nejznámějších chorvatských klavíristů Lovra Pogoreliče v Praze. Pořad připravila Tajana Mančalová, moderuje Tomáš Pilát.Všechny díly podcastu Mezi námi můžete pohodlně poslouchat v mobilní aplikaci mujRozhlas pro Android a iOS nebo na webu mujRozhlas.cz.

"You take a sad song and make it better..."   Hey Paul - thanks for the lyrics (even though we don't mention the Beatles AT ALL in this show.)   Tonight we honor the massive musical talent we lost in 2022... poorly, just like you expect from your hosts.    Eric & El Carpe roll through the songs from the bands these folks were part of... part of the bands, and part of our lives.     We played songs from bands like, The Specials, Primal Scream, The Tubes, PIL, The Pogues, Nazareth, Depeche Mode, Foo Fighters, Happy Mondays, Suicidal Tendencies, Foreigner, Olivia Newton John, (not Olivia Newtron Bomb), The Rascals, Meatloaf, Q Lazzarus, and the Stranglers...  to name just a few.   Not to mention others we lost others like Monty Norman who composed the 007 Theme Song, Coolio (we did a show earlier this year devoted only to him), Jerry Lee Lewis and Loretta Lynn.   Lot of talent gone, but they left behind a catalog of amazing and varied music for us and generations to hear and enjoy... and make new memories.  Thanks for all the creative talent you gave us !   Somehow we turned as sad story into something fun.  We hope you enjoy listening to our mess as we try to honor the talent we lost this year. May your 2023 rock and roll (koochie-koo)... Join us for more fun as we continue to hack our way through the next year of musical silliness... Eric has some great ideas, and El Carpe is his bitch... so will do whatever he wants.   It's gonna be fun, join us !   Pour Me Another Brother !

È stato presentato oggi il 56° Rapporto sulla Situazione sociale del Paese del Censis. Il ritratto che ne emerge presenta quasi tutti gli italiani convinti che l'inflazione salirà ancora, e la maggior parte è convinta che il proprio tenore di vita scenderà. Per questo risultano oggi odiosi per la stragrande maggioranza i privilegi e le ostentazioni di ricchezza. Le disparità più odiate dagli italiani sono quindi il gap tra le retribuzioni dei dipendenti e dei manager, i bonus milionari di buonuscita per i 'top' ("pagati per andarsene piuttosto che per lavorare"); le tasse troppo ridotte dei giganti del web; i "facili guadagni" di personaggi come gli influencer, ritenuti "senza un comprovato talento e competenze certe", ma anche, le feste sfarzose dei vip e i loro jet privati, lo sfoggio di auto e suv potenti, di ville con giardini e piscine, e poi l'esibizione (anche sui social) di vacanze, cene, hotel e locali di gran lusso. Altri numeri che non rendono felici sono quelli dello "tsunamidemografico", la fascia di età over 65 anni passera dall'attuale 23% della popolazione al 33% in soli venti anni. Ne parliamo con Massimiliano Valerii, Direttore generale del Censis. Roma e Milano primi comuni per Pil dal turismo Città d'arte campioni nella creazione di ricchezza turistica e centinaia di comuni si rivelano dei top performer del Pil grazie all'industria dell'ospitalità. Al primo posto della classifica ecco Roma con circa 7,6 miliardi di euro seguita da Milano con circa 3,5 miliardi, Venezia che supera di poco i 3 miliardi e Firenze con più di 2,8 miliardi. Non mancano poi le sorprese come San Michele al Tagliamento che grazie alla frazione Bibione riesce a battere la rinomata costiera amalfitana, Cavallino-Treporti supera Taormina e Chioggia lascia al tappeto Ischia. Sono questi i sorprendenti comuni campioni del valore aggiunto generato dalle attività turistiche. È quanto emerge dallo studio «La ricchezza dei comuni turistici - Ranking secondo la creazione di valore aggiunto», preparato da Sociometrica elaborando i dati Istat. Il focus dello studio è sui primi 500 comuni per presenze turistiche, dove si concentra l'83% del totale degli ospiti.Oltre alla classifica dei comuni italiani per Pil dal turismo, Sociometrica ha anche stimato l'andamento del 2022 che vede l'avvicinarsi dei flussi ai livelli del 2019. In termini di presenze complessivamente lo studio stima per quest'anno 389,4 milioni di presenze contro i 436,7 milioni del 2019 con un gap del 10,8%. In termini di valore aggiunto generato dalle presenze turistiche nel 2022 si superano gli 89,1 miliardi di euro contro i 99,9 miliardi del 2019. Quindi un settore in forte ripresa che si avvicina ai livelli pre pandemia anche se, per riuscire a raggiungere i livelli del 2019, sarà necessario fare i conti con il caro energia, che potrebbe mettere in pericolo la sostenibilità di tante attività, oltre che la diminuzione della domanda a causa dei prezzi in forte salita. E la questione occupazionale, con alcune professioni difficili da reperire sul mercato. Ne parliamo con Antonio Preiti, economista e direttore di Sociometrica. La nuova frontiera della calzatura marchigiana: addio a Russia e Ucraina, ora si va verso Stati Uniti e Cina Nove mesi di guerra e le sanzioni a Mosca hanno spinto gli imprenditori del distretto Fermano-Maceratese a spostare i pesi del business altrove. Dopo Russia e Ucraina, la nuova frontiera della calzatura marchigiana sono Stati Uniti, grazie al cambio favorevole, e Cina, dove dopo due anni di blackout sono ripresi gli acquisti delle griffe. Sono diventati rispettivamente il secondo e terzo mercato di sbocco dopo la Germania. Così la Russia scivola all'ottavo posto tra le destinazioni: con poco meno di 31 milioni di euro fatturati nei primi 6 mesi di quest' anno e una perdita del -24% rispetto all'anno scorso -37% rispetto al 2019. L'export in Ucraina oggi è impalpabile con 2,2 milioni fatturati. L'export complessivo del comparto nel primo semestre è comunque stato positivo: 627 milioni fatturati, +28,7% rispetto allo stesso periodo dell'anno precedente e appena -3,3% raffrontato con il 2019, l'anno del pre-covid. Approfondiamo il tema con Valentino Fenni, Presidente della Sezione Calzature di Confindustria Fermo e vice Presidente di Assocalzaturifici. Lavazza, bonus contro il carovita e venerdì breve Venerdì breve, permessi caregiving, estensione del congedo di paternità, ampliamento dello smart working. Sono alcuni dei principali punti del contratto integrativo del gruppo Lavazza approvato a larga maggioranza dai lavoratori del Centro Direzionale. L'accordo, che avrà efficacia per il triennio 2023-2025 integra gli aspetti legati ai piani di sviluppo del Gruppo, all'evoluzione dell'organizzazione del lavoro, alla valorizzazione dei collaboratori e al welfare aziendale dei circa 1.000 dipendenti impiegati negli uffici di 'Nuvola' a Torino e del centro di Settimo Torinese. Nello specifico entro il prossimo 12 gennaio un bonus speciale una tantum per andare incontro al caro vita, del valore complessivo di 700 euro totalmente detassati e articolato in forma di buoni acquisto, bonus carburante e rimborso delle utenze domestiche. L'inflazione, però, ha anche un rovescio della medaglia, e Lavazza come tutte le grandi aziende del food deve fare i conti con un aumento delle materie prime e dell'energia. Ne parliamo con Antonio Baravalle, amministratore delegato di Lavazza.

In questa edizione: - Mef, Pil in crescita del 3,7% nel 2022- Lavoro, al Sud più pensioni che stipendi- Pnrr, 6 miliardi per l'ambiente- Dolci delle festività, giro d'affari da 40 milionimgg/mrv

Il 2022 è stato un anno record: lo scorso ottobre il tasso di occupazione è salito al 60,5%, il valore più alto dal 1977, anno di inizio delle serie storiche. Inoltre nei primi nove mesi del 2022 sono state effettuate 6,2 milioni di assunzioni e si sono registrate 640.092 variazioni contrattuali per un totale di 6.867.184 attivazioni di contratto, recuperando e superando i livelli pre-pandemia (+7,4%). Dati molto positivi, corretti leggermente dalla rilevazione del terzo trimestre, secondo la quale l'input di lavoro misurato in Ula (Unità di lavoro equivalenti a tempo pieno) è in lieve diminuzione rispetto ai tre mesi precedenti (-0,1% rispetto al secondo trimestre 2022), mentre rallenta la crescita su base annua (+2,7% rispetto al terzo trimestre 2021). Intanto il governo ha inserito una serie di misure in manovra che riguardano il Reddito di cittadinanza e voucher. Queste novità potranno aiutare le aziende a trovare lavoratori? Il mismatch tra domanda e offerta di lavoro che interessa il 46,4% delle assunzioni che equivalgono a oltre 177mila profili dei 382mila ricercati dalle aziende (Unioncamere e Anpal). Negli ultimi giorni sono anche usciti dati interessanti che riguardano le retribuzioni degli italiani. Nel 2020, rivela l'Istat, circa il 76% dei redditi lordi individuali (al netto dei contributi sociali) "non supera i 30.000 euro annui: la metà dei redditi lordi individuali si colloca tra 10.001 e 30.000 euro annui, oltre un quarto è sotto i 10.001 euro e soltanto il 3,7% supera i 70.000 euro". È credibile che i lavoratori con oltre 30mila euro lordi l'anno siano solo il 24% del totale? Approfondiamo il tema conFrancesco Seghezzi, direttore fondazione ADAPT, centro studi su lavoro e occupazione fondato da Marco Biagi. Il 13% dei contribuenti italiani paga quasi il 60% dell'Irpef versata Secondo il rapporto di Itinerari previdenziali e Cida (Confederazione italiana dirigenti e alte professionalità), presentato oggi al Cnel, sulla base dei redditi 2020 (dichiarazioni 2021), su poco più di 41 milioni di contribuenti sono appena 5 milioni a caricarsi il peso di quasi il 60% dell'Irpef versata nelle casse dello Stato. Dalla ricerca emerge come un numero sempre più esiguo di contribuenti paga sempre di più. Nello specifico il 13% dei contribuenti ha pagato gran parte degli oltre 278 miliardi necessari per il funzionamento dell'apparato Statale. Ne abbiamo parlato con Alberto Brambilla, presidente di Itinerari previdenziali. Mezzo milioni di poveri al sud a causa del caro energia. 1,2 milioni di giovani hanno lasciato il Mezzogiorno Oltre 760.000 potenziali nuovi poveri per lo shock energetico, di cui mezzo milione al Sud. È lo scenario delineato nel Rapporto Svimez 2022, giunto alla sua 49esima edizione, presentato, lunedì 28 novembre, alla Camera dei Deputati. Il mezzogiorno rischia la recessione. Nel 2023 il PIL meridionale si contrarrebbe fino a -0,4%, mentre quello del Centro-Nord, pur rimanendo positivo a +0,8%, segnerebbe un forte rallentamento rispetto al 2022. Il dato medio italiano dovrebbe attestarsi invece intorno al +0,5%. Il 2024 dovrebbe essere un anno di ripresa sulla scia del generale miglioramento della congiuntura internazionale, unitamente alla continuazione del rientro dall'inflazione. Si stima che il Pil aumenti nel 2024 dell'1,5% a livello nazionale, per effetto del +1,7% nel Centro-Nord e dello +0,9% al Sud. Un altro elemento che emerge dall indagine riguarda l ambito della formazione, e in particolare l università. Secondo Svimez, infatti, nel 2041 il Mezzogiorno perderà il 27% degli iscritti, il Centro Nord circa il 20%. Negli ultimi vent'anni circa 1,2 milioni di giovani ha lasciato il Mezzogiorno. Uno su 4 è laureato. Ne parliamo con Luca Bianchi, direttore dello Svimez.

L'idea che l'Italia sia ancora il paese che cresce economicamente meno di tutti, che sia l'eterno "fanalino di coda", è un cliché duro a morire. Nemmeno di fronte ad un aumento del pil nazionale che nel biennio 2021-2022 supererà sicuramente il 10 per cento, i detrattori dell'Italia e i pessimisti a oltranza sono disposti a ricredersi. Eppure, i numeri parlano chiaro. La ragione è da ricercare nel fatto che l'economia nazionale degli ultimi 6-7 anni non è più quella che ha stentato fino al 2015. Ne parliamo con Marco Fortis, docente di Economia industriale e Commercio estero presso la Facoltà di Scienze politiche dell'Università Cattolica di Milano, nonché direttore e vicepresidente della Fondazione Edison. Prometeia alza la stima del Pil 2022 a +3,9%, +0,4% nel 2023 È stato presentato oggi il Rapporto di Previsione di Prometeia dal titolo "Recessione profonda o leggera?". Il dato che è emerge è un rialzo della stima di crescita del Pil italiano per il 2022 a +3,9% rispetto alla stima +3,4% di settembre. Viene migliorata anche la previsione per il 2023 dal +0,1% al +0,4%. Più in alto della media dell'Eurozona. Per quanto riguarda l'inflazione invece Prometeia si rivela ottimista e prevede che "nel corso del 2023 l'inflazione scenda in modo rapido, attestandosi al 5,8% contro l'8,4% del di quest'anno. L'Italia risulta in testa per crescita rispetto agli altri tre maggiori Paesi della zona euro, avendo già recuperato nel terzo trimestre di quest'anno i livelli pre-crisi (+0,3% rispetto al quarto trimestre 2019), mentre la Germania (-2,3%), la Spagna (-4%) e la Francia (-5,6%) appaiono tutte in forte ritardo. Ne parliamo con Stefania Tomasini, Senior Partner e Responsabile Analisi e Previsioni Economiche di Prometeia. Borse affondano dopo la Bce La Bce si somma alla Fed e conferma che serviranno ulteriori strette e che l'inflazione resterà troppo alta ancora a lungo. La Banca centrale europea, come atteso, ha alzato i tassi di interesse di 50 punti base portando i tassi sulle operazioni di rifinanziamento principali, sulle operazioni di rifinanziamento marginale e sui depositi presso la banca centrale rispettivamente al 2,5%, al 2,75% e al 2%. Ma peggiora le prospettive sull'inflazione. Il nuovo rialzo dei tassi della Bce si ripercuote con effetto immediato sullo spread tra BTp e Bund. Il differenziale di rendimento tra il BTp benchmark decennale italiano e il pari scadenza tedesco è indicato a 205 punti, 13 in più rispetto alla vigilia e 11 in più rispetto all apertura. In sensibile aumento anche il rendimento del BTp decennale benchmark, indicato ora al 4,08% rispetto al 3,85% di ieri sera e al 3,90% di stamattina. Nel pomeriggio il mercato è tornato a percepire il debito italiano come più rischioso rispetto a quello della Grecia lungo tutta la curva dei rendimenti. Il Btp decennale balza al 4,08%, in crescita di circa 20 punti base, mentre quello della Grecia si attesta al 4,037%, in crescita di solo 5 punti. Ne parliamo con Donato Masciandaro, docente politiche monetarie università Bocconi, ed editorialista Sole 24 Ore.

Cyklus Tomáše Piláta Jak se vrací krása filmům aneb Cesty českých snímků z krabice přes laboratoř zpátky na plátna se na příkladu čtyř legendárních titulů věnuje především zásadám, problémům a specifikům jejich digitální záchrany. Extáze, Ukradená vzducholoď, Až přijde kocour a Ucho – každý z těchto filmů byl natočen v jedinečném obrazovém i zvukovém formátu, který určil způsoby digitální restaurace. A samozřejmě přinesl i nečekané těžkosti. Všechny díly podcastu Mozaika můžete pohodlně poslouchat v mobilní aplikaci mujRozhlas pro Android a iOS nebo na webu mujRozhlas.cz.

Cyklus Tomáše Piláta Jak se vrací krása filmům aneb Cesty českých snímků z krabice přes laboratoř zpátky na plátna se na příkladu čtyř legendárních titulů věnuje především zásadám, problémům a specifikům jejich digitální záchrany. Extáze, Ukradená vzducholoď, Až přijde kocour a Ucho – každý z těchto filmů byl natočen v jedinečném obrazovém i zvukovém formátu, který určil způsoby digitální restaurace. A samozřejmě přinesl i nečekané těžkosti. Všechny díly podcastu Mozaika můžete pohodlně poslouchat v mobilní aplikaci mujRozhlas pro Android a iOS nebo na webu mujRozhlas.cz.

Cyklus Tomáše Piláta Jak se vrací krása filmům aneb Cesty českých snímků z krabice přes laboratoř zpátky na plátna se na příkladu čtyř legendárních titulů věnuje především zásadám, problémům a specifikům jejich digitální záchrany. Extáze, Ukradená vzducholoď, Až přijde kocour a Ucho – každý z těchto filmů byl natočen v jedinečném obrazovém i zvukovém formátu, který určil způsoby digitální restaurace. A samozřejmě přinesl i nečekané těžkosti. Všechny díly podcastu Mozaika můžete pohodlně poslouchat v mobilní aplikaci mujRozhlas pro Android a iOS nebo na webu mujRozhlas.cz.

Cyklus Tomáše Piláta Jak se vrací krása filmům aneb Cesty českých snímků z krabice přes laboratoř zpátky na plátna se na příkladu čtyř legendárních titulů věnuje především zásadám, problémům a specifikům jejich digitální záchrany. Extáze, Ukradená vzducholoď, Až přijde kocour a Ucho – každý z těchto filmů byl natočen v jedinečném obrazovém i zvukovém formátu, který určil způsoby digitální restaurace. A samozřejmě přinesl i nečekané těžkosti. Všechny díly podcastu Mozaika můžete pohodlně poslouchat v mobilní aplikaci mujRozhlas pro Android a iOS nebo na webu mujRozhlas.cz.

Cyklus Tomáše Piláta Jak se vrací krása filmům aneb Cesty českých snímků z krabice přes laboratoř zpátky na plátna se na příkladu čtyř legendárních titulů věnuje především zásadám, problémům a specifikům jejich digitální záchrany. Extáze, Ukradená vzducholoď, Až přijde kocour a Ucho – každý z těchto filmů byl natočen v jedinečném obrazovém i zvukovém formátu, který určil způsoby digitální restaurace. A samozřejmě přinesl i nečekané těžkosti. Všechny díly podcastu Mozaika můžete pohodlně poslouchat v mobilní aplikaci mujRozhlas pro Android a iOS nebo na webu mujRozhlas.cz.

Kivégezné a vonalkódokat az Amazon IT Business     2022-12-22 06:21:27     Infotech Robot Az Amazonnál is robotoké a jövő a logisztikában – egyre több raktárban dolgoznak már gépi munkatársak. „Akik” viszont, mint kiderül, nem kedvelik a jól megszokott vonalkódokat Sokkal drágább lesz az iPhone 15 széria az eddigieknél GSMring     2022-12-22 08:04:15     Mobiltech USA Apple Okostelefon iPhone Az amerikai vállalat a következő évben piacra dobhatja az iPhone 15 szériát, ami a hírek szerint sokkal drágább lesz, mint az előd modellek. Mutatjuk, hogy mit tudunk róla. Az Apple az idei évben mutatta be az iPhone 14 sorozatot, ami soha nem látott árakat hozott el a cégnél, persze azt hozzá kell tenni, hogy leginkább Már a homo sapiens előtt, félmillió éve is hajózhattak a Földközi-tengeren Rakéta     2022-12-22 11:24:08     Tudomány Indonézia Fülöp-szigetek A mai, modern ember mindössze 200 ezer éve jelent meg a Földön, de a Földközi-tengert már 450 ezer éve átszelték – de felmerül az is, hogy az Indonézia és a Fülöp-szigetek közötti tengeren még ennél is régebb óta közlekedhetnek. Vörös riadót fújt a Google a ChatGPT chatbot miatt Bitport     2022-12-22 11:24:02     Infotech Google Állítólag más részlegektől irányítanak át csoportokat az MI-termékek fejlesztésére, annyira valós veszélynek tartják, hogy az új technológia belekarmol a vállalat keresőüzletébe. Minden eszközben otthon cserélhető akkumulátor? Könnyen valósággá válhat! PCWorld     2022-12-22 08:48:07     Mobiltech Európai Unió Telefon Okostelefon Az Európai Unió újabb szabályt vezethet be, ami nem csak az okostelefon-tulajdonosoknak lesz extrán jó hír. Sosincs késő: az utolsó pillanatban is vehetsz ajándékot Mínuszos     2022-12-22 06:33:46     Mobiltech Ajándék Okosóra Yettel Van, hogy az ünnepi ajándékbeszerzés az utolsó pillanatra marad, de pánikra semmi ok: egy menő mobilos kiegészítőt, például fülhallgatót vagy okosórát még most sincs késő beszerezni. Mobilok 0 forinttól Az új mobil beszerzését sokan karácsonyra tartogatják, a Yettelnél pedig érdemes körbenézni a korlátlan belföldi adatmennyiséget tartalmazó Prime t Megható üzenettel búcsúzott a NASA robotja Digital Hungary     2022-12-22 12:23:00     Infotech Világűr Robot NASA Utolsó üzenetét küldhette a NASA InSight leszállóegysége. A robot feladata az volt, hogy a vörös bolygó belsejének működését tanulmányozza. A mutáns szúnyogokat nem öli meg a rovarírtó 24.hu     2022-12-22 11:23:23     Tudomány Szúnyog Egy bizonyos mutációval rendelkező szúnyogok százszor több méreganyagot képesek túlélni, mint társaik. Ásványi minták alapján felfedhették a Ryugu aszteroida rejtélyes szülőhelyét​ in.hu     2022-12-22 10:21:01     Tudomány Világűr Meteor A szakértők ásványi anyagok nyomaira bukkantak a Ryugu aszteroida mintáiban, ezek tanulmányozása után pedig következtetéseket tudtak levonni a szülőhelyével kapcsolatban. Ez a felfedezés jobb betekintést enged a galaxisunk képződésének első éveibe.A Ryugu aszteroida ásványi anyagjait egy kutatócsoport elektronmikroszkóp és szekunder ion tömegspektr Magyarok is részt vesznek a Weave égboltfelmérő programban Tudás.hu     2022-12-22 09:48:07     Tudomány A Csillagászati és Földtudományi Kutatóközpont (CSFK) Csillagászati Intézetének kutatói is részt vesznek abban a programban, amelynek keretében a napokban készítette el első felvételeit a WEAVE nevű műszer. A négyméteres teleszkópra szerelt egyedülálló spektrográf különlegessége, hogy különálló optikai szálak segítségével egyszerre akár ezer objekt Most akkor lemond Elon Musk vagy sem? Rakéta     2022-12-22 07:12:09     Infotech Twitter Elon Musk Közösségi média Múlt hét végén a Twitter tulajdonos-vezérigazgatója szavazást írt ki a platformon arról, hogy ő maradjon-e a nagymúltú közösségi média vállalat első embere. A válaszadók úgy döntöttek, hogy Musknak le kell mondania, de, ahogyan a milliárdostól megszokhattuk, nem egyértelmű, hogy pontosan mi fog történni. Az EP nyilvános meghallgatásra hívta Elon Muskot Mínuszos     2022-12-22 07:33:32     Gazdaság Twitter Európai Parlament Elon Musk Az Európai Parlament (EP) meghívta Elon Muskot, a Twitter közösségi portál tulajdonosát, hogy vegyen részt a platformról szóló nyilvános meghallgatáson. Roberta Metsolának, az EP elnökének meghívólevele szerint az uniós testület “őszinte eszmecserét” akar folytatni a milliárdossal – közölte az elnök szóvivője. A Twitter “nem válhat akaratlanul a gy Románia taktikai robotrepülőgép-rendszereket vásárol az izraeli Elbittől Biztonságpiac     2022-12-22 05:39:04     Gazdaság Románia Repülőgép Izrael Robot Áfa Pilóta nélküli, taktikai-operatív repülőgép-rendszerek beszerzéséről írt alá keretmegállapodást kedden a román védelmi minisztérium (MAPN) az izraeli Elbit Systemsszel. A MAPN közleménye szerint az öt éven belül leszállítandó hét Watchkeeper X típusú robotrepülőgép-rendszer teljes beszerzési költségét áfa nélkül 1,89 milliárd lejben (155 milliárd f

Kivégezné a vonalkódokat az Amazon IT Business     2022-12-22 06:21:27     Infotech Robot Az Amazonnál is robotoké a jövő a logisztikában – egyre több raktárban dolgoznak már gépi munkatársak. „Akik” viszont, mint kiderül, nem kedvelik a jól megszokott vonalkódokat Sokkal drágább lesz az iPhone 15 széria az eddigieknél GSMring     2022-12-22 08:04:15     Mobiltech USA Apple Okostelefon iPhone Az amerikai vállalat a következő évben piacra dobhatja az iPhone 15 szériát, ami a hírek szerint sokkal drágább lesz, mint az előd modellek. Mutatjuk, hogy mit tudunk róla. Az Apple az idei évben mutatta be az iPhone 14 sorozatot, ami soha nem látott árakat hozott el a cégnél, persze azt hozzá kell tenni, hogy leginkább Már a homo sapiens előtt, félmillió éve is hajózhattak a Földközi-tengeren Rakéta     2022-12-22 11:24:08     Tudomány Indonézia Fülöp-szigetek A mai, modern ember mindössze 200 ezer éve jelent meg a Földön, de a Földközi-tengert már 450 ezer éve átszelték – de felmerül az is, hogy az Indonézia és a Fülöp-szigetek közötti tengeren még ennél is régebb óta közlekedhetnek. Vörös riadót fújt a Google a ChatGPT chatbot miatt Bitport     2022-12-22 11:24:02     Infotech Google Állítólag más részlegektől irányítanak át csoportokat az MI-termékek fejlesztésére, annyira valós veszélynek tartják, hogy az új technológia belekarmol a vállalat keresőüzletébe. Minden eszközben otthon cserélhető akkumulátor? Könnyen valósággá válhat! PCWorld     2022-12-22 08:48:07     Mobiltech Európai Unió Telefon Okostelefon Az Európai Unió újabb szabályt vezethet be, ami nem csak az okostelefon-tulajdonosoknak lesz extrán jó hír. Sosincs késő: az utolsó pillanatban is vehetsz ajándékot Mínuszos     2022-12-22 06:33:46     Mobiltech Ajándék Okosóra Yettel Van, hogy az ünnepi ajándékbeszerzés az utolsó pillanatra marad, de pánikra semmi ok: egy menő mobilos kiegészítőt, például fülhallgatót vagy okosórát még most sincs késő beszerezni. Mobilok 0 forinttól Az új mobil beszerzését sokan karácsonyra tartogatják, a Yettelnél pedig érdemes körbenézni a korlátlan belföldi adatmennyiséget tartalmazó Prime t Megható üzenettel búcsúzott a NASA robotja Digital Hungary     2022-12-22 12:23:00     Infotech Világűr Robot NASA Utolsó üzenetét küldhette a NASA InSight leszállóegysége. A robot feladata az volt, hogy a vörös bolygó belsejének működését tanulmányozza. A mutáns szúnyogokat nem öli meg a rovarírtó 24.hu     2022-12-22 11:23:23     Tudomány Szúnyog Egy bizonyos mutációval rendelkező szúnyogok százszor több méreganyagot képesek túlélni, mint társaik. Ásványi minták alapján felfedhették a Ryugu aszteroida rejtélyes szülőhelyét​ in.hu     2022-12-22 10:21:01     Tudomány Világűr Meteor A szakértők ásványi anyagok nyomaira bukkantak a Ryugu aszteroida mintáiban, ezek tanulmányozása után pedig következtetéseket tudtak levonni a szülőhelyével kapcsolatban. Ez a felfedezés jobb betekintést enged a galaxisunk képződésének első éveibe.A Ryugu aszteroida ásványi anyagjait egy kutatócsoport elektronmikroszkóp és szekunder ion tömegspektr Magyarok is részt vesznek a Weave égboltfelmérő programban Tudás.hu     2022-12-22 09:48:07     Tudomány A Csillagászati és Földtudományi Kutatóközpont (CSFK) Csillagászati Intézetének kutatói is részt vesznek abban a programban, amelynek keretében a napokban készítette el első felvételeit a WEAVE nevű műszer. A négyméteres teleszkópra szerelt egyedülálló spektrográf különlegessége, hogy különálló optikai szálak segítségével egyszerre akár ezer objekt Most akkor lemond Elon Musk vagy sem? Rakéta     2022-12-22 07:12:09     Infotech Twitter Elon Musk Közösségi média Múlt hét végén a Twitter tulajdonos-vezérigazgatója szavazást írt ki a platformon arról, hogy ő maradjon-e a nagymúltú közösségi média vállalat első embere. A válaszadók úgy döntöttek, hogy Musknak le kell mondania, de, ahogyan a milliárdostól megszokhattuk, nem egyértelmű, hogy pontosan mi fog történni. Az EP nyilvános meghallgatásra hívta Elon Muskot Mínuszos     2022-12-22 07:33:32     Gazdaság Twitter Európai Parlament Elon Musk Az Európai Parlament (EP) meghívta Elon Muskot, a Twitter közösségi portál tulajdonosát, hogy vegyen részt a platformról szóló nyilvános meghallgatáson. Roberta Metsolának, az EP elnökének meghívólevele szerint az uniós testület “őszinte eszmecserét” akar folytatni a milliárdossal – közölte az elnök szóvivője. A Twitter “nem válhat akaratlanul a gy Románia taktikai robotrepülőgép-rendszereket vásárol az izraeli Elbittől Biztonságpiac     2022-12-22 05:39:04     Gazdaság Románia Repülőgép Izrael Robot Áfa Pilóta nélküli, taktikai-operatív repülőgép-rendszerek beszerzéséről írt alá keretmegállapodást kedden a román védelmi minisztérium (MAPN) az izraeli Elbit Systemsszel. A MAPN közleménye szerint az öt éven belül leszállítandó hét Watchkeeper X típusú robotrepülőgép-rendszer teljes beszerzési költségét áfa nélkül 1,89 milliárd lejben (155 milliárd f

⬇⬇⬇APRIMI⬇⬇ Abbonati qui: https://www.patreon.com/join/EconomiaItalia? https://www.youtube.com/economiaitalia/join Qui per segnalare temi: https://tellonym.me/dr.elegantia Podcast (su tutte le piattaforme): https://www.spreaker.com/show/dr-elegantia-podcast COME SOSTENERCI: Il nostro nuovo libro sull'economia: Guida Terrestre per Autoeconomisti https://www.poliniani.com/product-page/guida-terrestre link acquisto Amazon: https://amzn.to/36XTXs8 Acquistando le nostre T-shirt dedicate ai dati stampate in Serigrafia Artigianale con passione e orgoglio dai detenuti del Carcere Lorusso e Cutugno di Torino https://bit.ly/3zNsdkd e urly.it/3nga1 Guida al VOTO 2022: https://amzn.to/3KflXHd I vincitori della Coppa del Mondo possono contare su una spinta economica? Periodicamente, ogni quattro anni, i media e gli analisti sostengono che il vincitore della Coppa del Mondo FIFA subirà un aumento del PIL grazie a un'ondata di orgoglio nazionale che si tradurrà in una maggiore attività economica. Quanto c'è di vero in questa affermazione? Cerchiamo di fare un po' di chiarezza. DonazionI Paypal: https://paypal.me/appuntiUAB Vuoi sostenermi ma non sborsare nemmeno un euro? Usa questo link per per il tuo prossimo acquisto su Amazon: https://amzn.to/2JGRyGT Qui trovi i libri che consiglio per iniziare a capirne di più sull'economia: https://www.youtube.com/watch?v=uEaIk8wQ3z8 È tornata l'offerta di Buddybank. 25€ per ogni conto aperto. Io ho un conto buddybank da oltre un anno. Devo dire super top. Zero commissioni sui bonifici. No canone. Inserisci il codice E7B9B0 in fase di richiesta di apertura conto corrente buddybank. Scarica l'app qui: https://app.adjust.com/qpkbnd2 Dove ci trovi: https://www.umbertobertonelli.it/info/ https://linktr.ee/economiaitalia La mia postazione: Logitech streamcam https://amzn.to/3HR6xq0 Luci https://amzn.to/3n6qtgP Shure MV7https://amzn.to/3HRh7k1 Asta https://amzn.to/3HSRvzY #economiaitalia #dreleganzia #economia

Il controvalore dei contratti attualmente in circolazione ha superato i 620mila miliardi di dollari. Più di sei volte il Pil globale atteso quest'anno. Ecco perché rappresentano un fattore di rischio per gli equilibri della finanza globale

TESTO DELL'ARTICOLO ➜ www.bastabugie.it/it/articoli.php?id=7251PER ALZARE LA COPPA DEL MONDO MESSI HA DOVUTO INDOSSARE IL BISHT di Giuliano GuzzoTutte le grandi storie, quasi senza eccezioni, hanno dei retroscena o delle sbavature, delle piccole ombre che, se non offuscano la luce complessiva di una narrazione, un minimo comunque la ridimensionano. Sembra essere questo il caso del gesto compiuto dal calciatore di cui si parla di più, e giustamente, in questi giorni. Vale a dire il fuoriclasse argentino Lionel Messi, il quale - sollevando la Coppa del Mondo - ha indossato un bisht, un mantello tradizionale del golfo Persico e non solo.Come rilevato da più osservatori, quel mantello è pregno di significati, dal momento che rispecchia opulenza e prestigio. E il fatto che, a porlo sulle spalle di quello che è universalmente riconosciuto come l'erede - ora ancor di più - di Diego Armando Maradona, sia stato l'emiro del Qatar Tamim bin Hamad Al Thani - peraltro facendolo in mondovisione -, a detta di molti ha rappresentato la globale sottomissione dello sport più popolare del mondo al potere e all'economia qatariota.Esagerazioni? Probabilmente no. Lo stesso scandalo Qatargate, che sta investendo l'Unione europea in queste settimane, dimostra infatti che serve incassare un bel po' di banconote per convincersi e provare a convincere terzi che da quelle parti valori come i diritti umani, quelli dei lavoratori, delle minoranze e via di questo passo, contino qualcosa. Perché la realtà dice altro, se non l'opposto. In questo senso, sicuramente il gesto dell'emiro del Qatar risulta molto potente, anche se non va certo fatta colpa al solo Messi.Come infatti dimenticare le parole - per molti analisti pregne d ipocrisia - di Gianni Infantino, il presidente della FIFA, il quale durante la conferenza stampa inaugurale dei Mondiali di calcio in Qatar aveva affermato: «Oggi mi sento qatariota, mi sento arabo, mi sento africano, mi sento gay, mi sento disabile, mi sento un lavoratore migrante». E lo stesso Infantino, alla vigilia della finale del Mondiale, ha rincarato la dose di ipocrisia, rispondendo - ad una domanda proprio sui diritti umani - che «ora pensiamo ai tifosi di calcio».Ma torniamo alla politicizzazione, indubbia, dello sfoggio del bisht per un'altra considerazione, che è la seguente.Si fa bene, anzi benissimo a riconoscere nel mantello rifilato a Messi un gesto clamoroso e vergognoso, ai limiti come si diceva poc'anzi della sottomissione culturale. Però bisogna essere franchi: non è certo il solo caso. Come la mettiamo, infatti, con analoghe politicizzazioni che da anni si abbattono in Occidente su eventi che nulla hanno a che vedere con la politica? Si pensi al collettivo inginocchiarsi prima di una manifestazione, oppure il rosso sfoggiato ovunque in occasione della Giornata mondiale contro la violenza sulle donne, ricorrenza molto importante ma nel corso della quale è impossibile - salvo che uno non intenda affrontare una bella polemica - ricordare che il primo ad uccidere le donne è l'aborto volontario. E ancora: come la mettiamo con i nastrini arcobaleno esibiti da star, influencer e sportivi di ogni livello, in teoria un simbolo contro le discriminazioni subite dalle minoranze sessuali ma, di fatto, un obolo alle più estreme rivendicazioni Lgbt, incluso l'utero in affitto?Come si può vedere, il discorso è molto ampio e non finisce né inizia in Qatar. Figuriamoci. Anzi, si può tranquillamente dire che la sudditanza di Lionel Messi all'emiro - sempre che sudditanza piena e consapevole sia poi stata -, è solo l'ultima di una lunga serie che si consumano ogni giorno in Occidente. Solo che queste ultime, anziché come tali, sono salutate anzi celebrate come "scelte di campo" coraggiose. Cosa ci sia mai di coraggioso in chi si accoda alla linea ideologica, se pensiamo ai cosiddetti diritti Lgbt, sposata non solo dalle più potenti cancellerie del pianeta, ma anche da colossi economici come Amazon, Apple o Disney, ecco, si fa fatica a capire.Come si fa fatica a comprendere chi - giustamente - si indigna per il gesto politico e di sottomissione di indossare un bisht, ma non si indigna allo stesso modo o affatto per i gesti politici e di sottomissione pro-Lgbt. Immaginate per un attimo un Lionel Messi - ovviamente non in Qatar, sarebbe stato impossibile - avvolto da una bandiera Lgbt per alzare la Coppa. Sarebbe stato un gesto salutato come forse il più coraggioso della storia. Non sarebbe stata sottomissione a politica e ideologia anche quella?Nota di BastaBugie: Lorenza Formicola nell'articolo seguente dal titolo "Affari e moschee, la rete del Qatar in Italia" spiega perché da 15 anni il Qatar fa grandi investimenti nel nostro Paese: moda, hotel di lusso, grattacieli. Il Qatar investe molto per diffondere l'islam, di qui i progetti sul territorio italiano di diverse moschee e scuole coraniche.Ecco l'articolo completo pubblicato su La Nuova Bussola Quotidiana il 19 dicembre 2022:L'hanno chiamato Qatargate e ha tutta l'aria di essere uno scandalo appena all'inizio. I servizi di sicurezza di ben cinque Stati europei indagano sul tentativo di corruzione di parlamentari dell'Unione Europea: un presunto sistema tangentizio, con lo scopo principale di incidere sui dossier in corso di istruzione all'Eurocamera. Un'indagine che ogni giorno s'ingrossa di più. Ad essere coinvolti fin qui nell'inchiesta sono soprattutto i politici dell'ala socialdemocratica del Parlamento e tra questi anche diversi italiani. Ci sono, per esempio, l'ex eurodeputato del Pd, oggi Articolo Uno, Antonio Panzeri, sospeso dopo lo scandalo, ma anche Niccolò Figa-Talamanca della Ong No Peace Without Justice, fondata nel 1993 da Emma Bonino.Ma quello tra Italia e Qatar non è un sodalizio recente. Tessere una rete di conoscenze capaci di influenzare è una strategia di Doha a livello globale che vede, da anni, nell'Europa un tassello fondamentale e nell'Italia un Paese di particolare interesse. Gli investimenti strategici nel corso degli anni si sono sprecati. Doha, attraverso la Qatar Investment Authority (Qia), il fondo sovrano del Paese creato nel 2005 per investire in tutto il mondo, ha investito estensivamente in Italia negli ultimi quindici anni. Un tesoro il cui valore sarebbe intorno ai cinque miliardi di euro. Il Qatar, grande poco più dell'Abruzzo, al 2022 conta una popolazione di tre milioni di persone per un Pil di 223 miliardi di euro e un Pil pro-capite che è più del doppio di quello italiano.È il 1995 l'anno della svolta per il Paese, quando, con un colpo di Stato, Hamad bin Khalifa Al Thani spodesta il padre e diventa emiro. L'obiettivo è subito trasformare il piccolo Stato in potenza globale: gli ingenti proventi dell'industria di gas e petrolio gli tengono le spalle coperte e già nel 1996 finanzia con 150 milioni di dollari la costituzione dell'emittente televisiva Al Jazeera che negli anni è diventata, secondo la Bbc, il più importante canale di informazione in lingua araba del mondo. E nel frattempo Al Thani inizia una lunga e florida amicizia con la Fratellanza Musulmana per puntare, attraverso il tessuto religioso, culturale ed economico all'espansione verso l'Occidente, Italia inclusa.Il Qatar è da tempo un importante partner, per il nostro Paese, sull'energia: riceviamo, per un contratto a lungo termine sottoscritto da Edison, 6,5 miliardi di metri cubi di gas l'anno, cioè più del 10 per cento del totale del gas che l'Italia acquista dall'estero. Ma l'amicizia Italia-Qatar non si limita all'energia. Moda, hotel di lusso, Costa Smeralda, Milano: la lista degli affari del Qatar in Italia ogni anno s'arricchisce. Nel 2021, le esportazioni qatariote verso l'Italia sono state pari a 2,1 miliardi di euro, cifre che procedono così, senza particolari variazioni, dal 2019; inoltre, siamo il secondo Paese europeo fornitore del Qatar (dopo la Germania) e il decimo al mondo.A Milano, il Qia possiede l'Hotel Gallia, un 5 stelle acquistato nel 2006. E in pochi anni è diventato proprietario del Gritti Palace, a Venezia, del St. Regis e dell'Excelsior a Roma, del Baglioni e del Four Seasons Hotel a Firenze. Riguardo alla moda, nel 2012, il Qatar compra la maison Valentino per 700 milioni di euro. Nello stesso anno viene acquistata per 650 milioni di euro la Smeralda Holding che possiede alberghi di lusso: 2300 ettari di terreni immacolati nella costa gallurese che diventano quattro alberghi. A maggio del 2014, Pigliaru presidente e Renzi premier firmano un accordo con Rispo, responsabile per l'Italia della Qatar Foundation Endowment: nasce l'ospedale Mater Olbia. Nel 2015, tocca di nuovo a Milano. I grattacieli di Porta Nuova, simbolo della skyline del capoluogo lombardo, diventano di Doha per 2 miliardi. Nel 2016, viene comprato l'albergo San Domenico di Taormina e, a fine settembre 2017, Qatar Airways conclude l'iter di acquisizione del 49% di Meridiana.La politica estera si realizza anche con le forniture militari e l'Emirato, negli anni, è diventato ottimo cliente del complesso militar-industriale italiano. Nel 2016, il Qatar firma con Fincantieri l'acquisto di quattro corvette, due pattugliatori d'altura e una nave anfibia multiruolo con un contratto di quattro miliardi di euro.

Al Consiglio Affari Energia, a quanto si apprende da fonti europee, è stato trovato un accordo politico sul price cap a 180 euro a megawattora. Sulla base dell'intesa politica raggiunta al Consiglio Affari Energia il price cap al gas entrerà in vigore il 15 febbraio prossimo. A quanto si apprende da fonti europee il differenziale del prezzo al Ttf con gli indici di riferimento globali viene fissato, come previsto nell'ultima proposta della presidenza ceca, a 35 euro. I giorni necessari - in cui il prezzo deve superare i 180 euro a megawattora - perché scatti il meccanismo di correzione restano tre. Ne parliamo conAdriana Cerretelli, editorialista de Il Sole 24 Ore. Consumo di beni durevoli: -2% rispetto al 2021. Si spende principalmente per la casa. Sono stati presentati la scorsa settimana i dati dell'Osservatorio Findomestic 2022, dedicato al mercato dei beni durevoli, realizzato dalla società di credito al consumo del Gruppo Bnp Paribas in collaborazione con Prometeia. La spesa delle famiglie in beni durevoli a fine anno toccherà quota 69,1 miliardi di euro con una contrazione del 2% rispetto al 2021, attribuibile ad una riduzione dei volumi (-7.6%) solo parzialmente compensata dalla crescita dei prezzi (+6.1%). Gli acquisti per la casa (+2,6%) tengono a galla il mercato dei beni durevoli compensando, almeno in parte, il crollo del settore motori (-6,2%). Risultano in calo, invece, gli altri capitoli di spesa: -3,4% le auto usate, -7,2% l'information technology, -10,6% le auto nuove (domanda dei privati) e -12,2% per Tv/Hi-Fi. Approfondiamo il tema con Claudio Bardazzi - Responsabile dell Osservatorio Findomestic. Prometeia alza la stima del Pil 2022 a +3,9%, +0,4% nel 2023 È stato presentato oggi il Rapporto di Previsione di Prometeia dal titolo "Recessione profonda o leggera?". Il dato che è emerge è un rialzo della stima di crescita del Pil italiano per il 2022 a +3,9% rispetto alla stima +3,4% di settembre. Viene migliorata anche la previsione per il 2023 dal +0,1% al +0,4%. Più in alto della media dell'Eurozona. Per quanto riguarda l'inflazione invece Prometeia si rivela ottimista e prevede che "nel corso del 2023 l'inflazione scenda in modo rapido, attestandosi al 5,8% contro l'8,4% del di quest'anno. L'Italia risulta in testa per crescita rispetto agli altri tre maggiori Paesi della zona euro, avendo già recuperato nel terzo trimestre di quest'anno i livelli pre-crisi (+0,3% rispetto al quarto trimestre 2019), mentre la Germania (-2,3%), la Spagna (-4%) e la Francia (-5,6%) appaiono tutte in forte ritardo. Ne parliamo con Stefania Tomasini, Senior Partner e Responsabile Analisi e Previsioni Economiche di Prometeia. Manovra, le ultime novità: dalle pensioni al Pos La Manovra, stando alle ultime novità, dovrebbe confermare l'aumento a 600 euro delle pensioni minime per gli over 75, modifica che verrà introdotta con un emendamento ancora in via di definizione, che conterrà anche la proroga al 31 dicembre 2022 del superbonus al 110%. Restano le sanzioni agli esercenti che non accettano pagamenti elettronici, mentre slitta al 31 marzo 2023 lo stralcio delle cartelle esattoriali fino a mille euro. Riduzione da otto a sette mensilità del Reddito di cittadinanza per gli occupabili, che vale 200 milioni di euro. E taglio del cuneo fiscale del 3% sale per i redditi fino a 25mila euro. Analizziamo le ultime novità insieme a Gianni Trovati del Sole 24 Ore.

«Tutti, sia gli osservatori nazionali sia quelli internazionali dicono che l'anno prossimo ci sarà un rallentamento dell'economia, rallentamento che purtroppo è già iniziato. Nel terzo trimestre, pur in presenza di un Pil positivo, se guardiamo il dato disaggregato per la manifattura, ha già segnato -0,5%». Lo ha affermato il presidente di Confindustria, Carlo Bonomi, all'assemblea di Confagricoltura, aggiungendo che il dato di settembre è stato -1,7%, il dato di ottobre appena uscito -1%. «La frenata si vede e questo ci preoccupa perché questo non consente di avere quelle risorse extra aggiuntive di cui ha potuto usufruire il governo Draghi per intervenire sugli shock soprattutto quello energetico, che abbiamo dovuto sostenere», ha spiegato Bonomi.

He's here, he's there; Dr. Hillman brings drug safety everywhere! So given the rules and regulations he needs to follow, the title “vigilante” could be nothing but ironic.We chart David's progress through choosing pharmacology as a subject to study, and settling on pharmacovigilance as a career to pursue. Listen: The Bollywood beats come courtesy of Cambridge-based artist Anish Kumar whose music you can also find on Bandcamp: anishkumarmusic.bandcamp.com, YouTube, Instagram and Twitter.Watch:Subscribe to our YouTube channel now for all future recordings. Episode transcript[Background intro music playing is "Nazia" by Anish Kumar]Parmvir: Hello everyone. And welcome to another episode of the 2Scientists podcast, where inspiring scientists share their work with you, wherever you like to listen. Today we come to you from a rather unique spot, rather than a cafe or bar we are camped out in Kensington Gardens in London, because it's a glorious day and our podcasting equipment allows us to do that. But enough about me and us, we are here today, of course I am your host Parmvir Bahia here and we're here with David Basanta, but we also have with us another David who is very special to me, he is an old friend of mine from my PhD program, and we shared much time and much swearing over experiments together at University college London. How are you David Hillman? David: I'm doing well. Thank you. It's, as you say, it's a, it's a lovely day and, it's nice to be back with old friends. Parmvir: Yes, yes. Of course everything rotates background to COVID and whereas we would normally see each other once a year. It's been three, four, possibly? David: Three, I think that's yeah.Parmvir: Miserable. David: Yeah. Sad times we shall have to make up for it. Parmvir: We will, we will. There's a bottle of Cava with our name on it. Once we've done with this. David: And onion rings. Parmvir: And onion rings. Yes. Fancy Marks and Spencer's one's though. So let's start at the beginning. I'm not talking about like, where were you born kind of thing. Although you can mention Kidderminster if you'd like. So as I understand it, we had a relatively similar track as undergraduates. So you did a bachelor's in pharmacology, correct? David: Yeah, that's right. Parmvir: So tell us why, why pharmacology? David: So this is gonna age me, age us.So I, for my A levels, so for my senior school exams, I, studied chemistry, biology, and maths, and I wanted to study something at university that combined chemistry and biology. And so this is the bit that will age us. So back in the day, if you remember, you would go to the, career advice department who were trying to help people to steer people towards what options they might want to pick at university.And they had this huge telephone directory effectively, which, mapped together people's different, combinations of A level courses and then gave you a list of options that you could, study at university. So I was sat in this little tiny room with this career advisor person, and they were basically running through this list of different courses.And when they came to pharmacology, they'd already mentioned pharmacy, which, you know, most people know what it is, but then they said pharmacology and I stopped them and said, well, what's, what's the difference? And they actually gave a pretty good summary. They said, it's more the biology of medicine. It's more the, the research and development of new medicines. They said it's potentially a controversial topic because it's the pharmaceutical industry is itself sometimes controversial and there's other aspects to the industry, which are, challenging sometimes. But yeah, that's how it started. So I picked a few different pharmacology courses, one of which was King's College London. I was always very practical, so I liked the idea of doing a year in industry at some point. So I chose a sandwich course like you and yeah, so that took me to KCL all that time ago. Parmvir: Mm. So I didn't realize how similar our tracks had been, because I also did biology, chemistry and maths, and I wanted to do something with the chemistry and the biology.And I got put in that direction by David: did you pick it out of the phone book as well? Parmvir: I did. What was it called? There was a name for it. David: It was pretty like a UCAS publication. Parmvir: Yes. It was just, it was enormous. David: Yeah. Parmvir: But yeah, in any case, I also, I did a sandwich year and I got to go and hang out in Germany for a year, which was fun.But yeah. So obviously after that you came to do a PhD at UCL where we were, well, I was a year ahead of you, I think. David: Yeah. You were. Parmvir: Why? Why did you do a PhD? David: So well for the reasons that I guess a lot of people do them, which is that I wasn't sure what to do next [both laugh] and a PhD seemed like a good way to string it out for another few years before I figured that out.But the reason I landed on UCL was that when I did go and do my year in industry, which like you was for a large pharma company, I worked in a lab looking at some non-clinical safety models. And we were using electrophysiology techniques at the time that was sharp electrode electrophysiology.Parmvir: You're gonna have to explain what electrophysiology means. David: Oh, don't make me do that. It's been 20 years [Parmvir laughs]. Oh, it's basically where you take either isolated cells or tissues and you put tiny, tiny electrodes into them and measure the changing currents across cell membranes. And as you put different drugs on, you can look at different effects of those drugs how they affect the electrical signals that you can measure.And really it's ions moving back and forward across membranes by little things called ion channels. So yeah, so I'd done sharp electrode electrophysiology there. I went back to university to finish my last year, and then the question came up about what to pick for a PhD. And I thought, well, although I hadn't enjoyed electrophysiology, it's something that I had started to, I guess, gain an interest in. Plus I had some skills that in that area. So, yeah, so I found a course, rather a PhD studentship at UCL, which seemed to fit the bill. It was looking at using a slightly different electrophysiology technique, so patch, clamping in a different area, but I thought it was something that I could use what I'd learnt in my year in industry Parmvir: I gave you some of these questions beforehand. David: Yes, because I'm incapable of spontaneous reaction to questions [Parmvir laughs]. Parmvir: Actually, I loved it so much that I have to read out your description of what your memory is like. David: I was quite proud of that. I coined that yesterday. I used to think of my memory as a lobster pot. Parmvir: All right. So you said I've just come up with a good analogy for my recall memory. It's like a reference library. You have to put in a request and then go away for a bit. When you come back, I'll have retrieved something from the vaults. Hopefully. David: Yeah, exactly. Parmvir: But aside from that I wanted to say this might be something of a loaded question, but what did you think of your PhD experience?David: You know, I really, I look back on those years with fond memory. Now it's partly because looking back, you edit out all of the stress and anxiety associated with doing a research project like that. I remember at the time when I first started UCL ran some induction courses where they pulled together PhD students and other postgraduate students from all sorts of backgrounds and John Foreman who you'll remember who was the Dean of students at the time, he gave a little introduction to UCL, but also gave some interesting advice let's say and pointers.And one of the things he pointed out in that session was the high degree of mental illness that is encountered by students in general taking these types of courses because they are stressful. And you often feel like you are kind of on your own. Driving your own research project forward. Sometimes through difficult times. So I do remember that in particular, but you know, what I remember mostly is just how impressed I was with all of the people that surrounded me because our department was not particularly flashy in its kind of presentation, but there were some seriously impressive people there.So I always like to think of our lab in the sense of, you know, it was run by effectively by Dennis and, and Guy when we got there. But before then it had been run by Don and before then it had been run by Bernard Katz who was a Nobel laureate. So it felt like we were the either grandchildren or great grandchildren of a Nobel Laureate and the whole department was a bit like that. It had a lot of very understated people who were world experts in their, in their field. And I always felt like the dumbest person in the department. But that didn't bother me too much because you know, being surrounded by all this greatness and even just, you know, the little glimpses of things you would see at the kind of coffee breaks and in the corridors, some of those memories still live with me, you know. Bearing in mind, this was back in what, between 2001 and 2005.So very, very early days of smartphones, things like trios and things like that, which seem antiquated now. But I remember coming across two old professors, so probably in their seventies or eighties comparing their smartphones and that like little microcosm, are the things that I loved about the department.Parmvir: Actually, I mean, I think you're, you're definitely selling yourself short. Like nobody would say that you weren't smart enough to be there. And I think one of the things that kind of ties into the, the mental health aspect is that we all felt that way. David: Yeah. Parmvir: Except we didn't express it to anyone else. It's, it's utterly ridiculous. How can we all be the least smart person in the room that's just not possible. David: Yeah. Parmvir: And after that, we all got our PhDs anyway, so, you know yeah. David: I certainly have no regrets about it. And I look back on those times with, with very fond memories, for sure. Parmvir: Yeah. Just talk briefly about what you did for your project and what the difficulties were.David: So the lab that I joined, so which, which you were a part of as well, their specialty was calcium activated potassium channels. And over time, the lab had looked at these ion channels in various different settings. The project that I was given was looking at these channels in vascular endothelial cells, which was a cell type that no one in the lab had ever studied before.Parmvir: Mm. David: So one of the biggest challenges that we were hit with straight away was that no one in the lab could really help that much with firsthand experience of how to obtain these cells, how to isolate them, how to culture them, how to grow them and really how to manage those cell types. So you might well remember that, the first, probably nine months of my PhD was just spent trying to culture these cells. Parmvir: Mm-hmm David: and it started with you know, available tissue from rats and other small mammals.But then eventually we were not having success with culturing cells from those models. So I switched onto pigs and, you know, I'd done a bit of reading that, you know, these vessels, because they were much larger the blood vessels, it was easier effectively to culture cells from, so I looked in the phone book and I found the address of an abattoir out in the middle of Essex.And there began my weekly trip for getting on for two and a half years to the deepest, darkest corners of Essex to go and retrieve pig, coronary artery cells once a week. Parmvir: Yeah. And essentially you suffered because these things were so flat. [David laughs] And when you're trying to, so you, for anyone who's listening, you have to picture trying to get a very, very fine tube onto something that is incredibly flat, and essentially you need this thing to form a vacuum seal and that just wasn't gonna happen. David: No, so, you know, vascular endothelial cells, they're the cells that line blood vessels, which is why they're, they're very flat. They're like tiles almost on the inside of veins and arteries.And you know, with other cells in the lab that were being looked at like the ones that you were looking at, like DRGs and like neurons and things like that, you know, you were basically putting the, the electrode down onto like a ball. Parmvir: Yeah. David: So the gap between the bottom of the dish and the top of the cell was who knows, 10, 20 microns, something like that. The cells that we were looking at, they flattened themselves out so much, they were about one micron, I think we estimated and therefore the tiniest vibration in the room would destroy the cell. And yeah, so the first stage was trying to culture, the damn things, and that was extremely challenging. It took a long time, but nine months of the way through managed it, and then began the whole pain of trying to get electrical recordings from them, which turned out to be as difficult. Parmvir: Yeah. So one of the things, I don't know if we ever talked about this, but what did you aspire to do after you'd done your PhD originally?Like, did you have any kind of idea? David: I mean, I think I was always headed into the pharmaceutical industry, which is where I landed up. In my undergrad degree in, I think my either first or second year, I did a very nice course, which was a kind of practical introduction to the pharmaceutical industry and from very top level, how drugs are developed and how pharma companies are organized internally and how the research progresses. And that, I'd always found that interesting. I mean, I find the entire pharmaceutical industry absolutely fascinating. And still do to this day. It's such an amazingly complex industry. And so, yeah, so I think I'd always been heading in that direction. Sure enough, the PhD certainly made me decide I was done with bench science [Parmvir laughs]. So, you know, by the time you've spent three plus years plodding along with these experiments that have a success rate of one in 50 sometimes. Parmvir: Yeah. David: You know, days and weeks without getting any data, and towards the end, still being in the lab at three o'clock in the morning, trying to get something to work and breaking more and more glassware as time goes on [Parmvir laughs]Yeah, I decided I was done with bench science, although I loved being in the labs, I loved playing in the labs. But I was never that into the kind of reading of the scientific papers and that sort of thing. Once it came down to maths and things like that, I wasn't so engaged. I needed to see practical things. Parmvir: Yeah. I feel like at some point we realized we were both some kind of engineer at heart rather than David: Yeah. Maybe Parmvir: scientist, David: maybe. Parmvir: It's more like, how does this work rather than trying to answer a bigger scientific question. David: Yeah. Parmvir: But obviously you were, you were a little bit scarred by your experience there, and you ended up going off in, I guess, a very different track from what the standard academic education leads you towards. So I think at this point this might be a good place to put your disclaimer in. David: Yes. So I work in the pharmaceutical industry and over time I've worked for, and with a variety of different companies.Any of the content that I describe today are my opinions and my opinions alone, and often they're really based off things which are in the public domain. In fact it's all based off things that were in the public domain and also some of the education that I've received, because actually, even after I finished my PhD, I then years later went on to study a, another academic course specifically in pharmacovigilance and pharmacoepidemiology.Parmvir: Oh, where did you do that? David: London school of Hygiene and Tropical Medicine. Parmvir: Oh. David: And it's interesting because it's a short course and I felt was a very valuable course. It's a course where regulatory authorities also send their people to learn too. Parmvir: So there's a lot of questions I can ask next.But one of the things that your job description throws up is this word "pharmacovigilance". What does that mean? David: Okay. So somewhere because I'm not gonna do it justice from memory, I'm going to read out the WHO definition of pharmacovigilance. It doesn't roll off the tongue, unfortunately, which is why it's never quite there in my head.So per the WHO: pharmacovigilance is the science and activities relating to the detection, assessment, understanding and prevention of adverse effects, or any other medicine, or vaccine-related problem. So essentially it is the process and the science relating to drug side effects. Now as you'll remember from pharmacology days, very early on, you're taught that all pharmacologically active substances, if it applies to the human body have side effects. The same side effects are not encountered by every person.And you know, some of the side effects might have obvious clinical manifestations. Some might not, you might get side effects, never know you've had them. And of course they vary massively in severity. So when you are looking at a medicine, particularly one that you're introducing to kind of general use in humans, you have a trade-off to make because you have an expected therapeutic benefit, but you also have to be mindful of potential side effects, particularly serious side effects and how much tolerance you have for those versus the good that the drug is supposed to do.And achieving that balance is one of the big challenges that's faced in drug development.Parmvir: So what you do really, it kind of comes at the end of the whole process of clinical trials and so on for given products, right? David: It actually starts right at the beginning of clinical development.So. Parmvir: Oh, hang on, I have to ask David's question: does that make you a Pharmacovigilante? David: [David and Parmvir laugh] I've often wondered the same thing myself. But yeah, so pharmacovigilance takes off really where toxicology leaves. So before you can put a drug into clinical development, by which I mean development in humans, drugs first have to go through preclinical development and that's where all the various toxicology studies are run.Parmvir: Can you quickly define toxicology for us? David: Sure. It is really focusing on the well, the potentially toxic side of medicines. So before you put a drug anywhere near a human, you want to be absolutely certain that it doesn't cause various catastrophic side effects in humans.So, for example, you need to be confident that it doesn't cause cancer. You need to be confident that it's not gonna cause a heart attack immediately, or cause a stroke immediately or things like that. So as per regulations in pretty much every country in the world, before you put a drug anywhere near a human in a clinical trial, it has to go through a standard set of tests.And there's various ways to achieve that. You know, sometimes those are tests using computer simulated models. Sometimes they are using individual cells or cultured cells or tissues. And sometimes as is well known in the industry they're using animal models and these are legally required tests.So every drug that goes through the process has to go through these. So that's done before it gets to clinical development. And then you start with phase one clinical trials which are studies on, usually on healthy volunteers and they're very small trials. They involve perhaps a few tens of patients. And the only purpose of those trials is to look at the safety and tolerability of the drug. So this is the first time you're putting the drug into humans. There is a bit of an exception to that. So although these are usually conducted on healthy volunteers, for some drugs, including, for example oncology drugs. Those drugs are usually along the more kind of toxic end of agents, so it's not ethical to put those into healthy volunteers. So sometimes those studies are conducted in a patient population. So once a drug moves into human studies into phase one, from that point, really for the rest of the lifetime of that drug as a human medicine pharmacovigilance is involved. So all the way through the phase one, two and three studies and then once the drug goes onto the market, pharmacovigilance continues.So the companies or the pharmaceutical or biotech companies that are developing these assets have a legal requirement to collect and analyze this data on an ongoing basis pretty much forever. Until that drug is eventually, perhaps if it's lucky enough to get to the market, until it's withdrawn from the market, perhaps many decades later.Parmvir: Very good. And I think that there are probably some very topical things that have come up recently as a result of COVID 19, which is important to consider when we're talking about these things, in that we are not just relying on these clinical trials that have gone out to ensure that these things are safe, but once they're out there that you have to continue to get feedback from people who are taking these to ensure that they continue to be safe in the long term, right?David: That's true. So, you know, ordinarily in clinical development, once you get through phase 1, 2, 3, and if you are lucky enough to have a drug, which is sufficiently efficacious, tolerable to go to market, then yes, you know, the drug's released to market and you continue to monitor for this stuff.Vaccines are in a particularly special category because they are drugs that are given to healthy people. Mm yes. And so therefore the benefit risk balance is more complicated in some ways, because , you know, it's, it's hard to consider the benefit to the individual of taking a product when they don't yet have that disease.So now there are other drugs that are in a similar category, other drugs that are given to healthy people. This is where I can ask you some questions. So what, what do you think those other drugs include? Parmvir: Oh, goodness. Um, I'm trying to think off the top of my head, what they might be. David: Yeah. It's very unfair. Parmvir: All I can think of at the moment are the other vaccines. David: Okay. So, Parmvir: but there are lots of prophylactic things. Yeah. Yeah. I can't think of anything David: Contraceptives. Parmvir: The obvious prophylactic. Yes. David: Drugs used for travel. So things like anti-malaria tablets. Parmvir: Oh yeah. David: Drugs used for things like smoking cessation Parmvir: mm-hmmDavid: stuff like that.So again, these are all drugs that are generally given to healthy people. So, you know, and this is where benefit risk balance comes into sharp focus, because if you have a drug that has been developed to treat a very hard to treat cancer, let's say, then when you consider benefit risk balance you know, if these patients are effectively going to die without a treatment, and this is the only treatment available, you might be able to accept that a drug has a one in a hundred chance of causing a fatal stroke. Particularly if that drug is given in hospital and these things can be, can be managed. If however, you are developing a cough medicine, then your tolerance for any type of dangerous side effects is basically zero, and of course, many drugs elsewhere on that scale. So yeah, benefit risk balance is a key part of what has to be looked at during drug development. And yeah, as we say, vaccines are particularly challenging. Often these days when a new drug is developed the clinical development and the studies don't stop necessarily when the drug is released for marketing. So, often as a condition of the marketing authorizations that are granted for these drugs, there have to be continuing studies to look at safety. These are called post-authorization safety studies. And so there's ongoing collection of data in a rigorous way to keep monitoring for various things. Either new things that we didn't know about the drug before, because of course when you're in clinical development, your number of patients is normally quite small Parmvir: mm-hmm David: so you're less likely to spot very rare side effects. You wouldn't usually detect a one in 50,000 probability side effect in a clinical trial cohort. Parmvir: Yeah. David: But sometimes these post authorization safety studies allow you to pick up more of that and enable you to characterize some of the side effects that you do know about more in detail.Parmvir: Yeah. So David B here asks essentially how long do these things go on after the drug's been on the market? For example, is there still pharmacovigilance for aspirin? David: Yes. Every single drug that has a marketing authorization out there it is the law in pretty much every country in the world that all safety data that becomes available to the marketing authorization holders, that's the company that owns the rights to the drug and effectively sells the drug, they're required by law to collect process, analyze and report this data. Now as drugs age, the natural reporting rate for some of these drugs drops so the probability of a physician or a pharmacist or a nurse, or even a patient reporting a side effect probably drops over time because theses are not new medicines anymore, but even so, any data that is collected has to go through that process, which is the pharmacovigilance that we were referring to earlier. In addition to that, all companies with marketing authorizations have to look at scientific and medical literature. It all has to be reviewed, so in European requirements, including the UK on a weekly basis, companies have to trawl some of the big literature databases, such as PubMed and M base, they have to trawl that information for any articles on their drugs. And any indication of side effects or other similar challenges. Parmvir: So how is this information collected and processed? Cause you've said obviously doctors, nurses, patients, they will all report certain things. Mm-hmm how do you kind of get them to a central place and cataloged and how do you decide what are actual side effects versus David: So if we think about the front end of the process, most pharma companies out there will have medical information help lines. So these are help lines that are set out there so that healthcare professionals. So that's the physicians, the, the pharmacists, the nurses and others but also consumers can contact the company for more information about the medicine and also potentially report adverse events, side effects. In parallel to that the same thing's going on with the regulators. So in the UK, for example, we have the yellow card scheme, which these days is a web portal system where anyone can go in and report side effects of medicines they're taking. In the us, you have the MedWatch scheme, which is very similar. Most companies around the world have similar things. Plus you've also got ongoing clinical trials, clinical studies, so data is coming in that way too. We've got data coming in from literature that I've mentioned. The regulators, when they receive stuff directly, they often pass that information over to the pharma company.So essentially all this information is coming towards the pharma company. It all gets directed to a pharmacovigilance department. And then we go through the process of processing that data. And so that data comes in from everywhere around the world where the drug is available for patients to take both in clinical trials and on the market.So the process basically consists of firstly translating the data, if it needs to be translated that gets captured into a safety database and there are various commercial safe databases out there. This is where companies collate all the information received on their drugs. And it goes through a process whereby data is kind of standardized it's put into standard terminology in a way that is compatible with the regulatory requirements. A narrative is constructed. So we write a story of what's happened to the patient from beginning to end. We look at various things like if the information is available to us, you know, what other medications were the patients taking? What's their medical history? What was the sequence of events? So what was the time to onset if possible, if we have that information between the patient taking the drug and them reporting the side effect, what the clinical course of the side effect was, so did the patient recover? Was any adjustment made to the the, the dosing or any treatments given? And so all that gets written up, we then decide what other information do we need to know?And then there's a feedback loop to go and ask the reporter if they'll provide additional information. Usually we ask for more information on more serious adverse events. We don't wanna overburden the reporters. Now reporters in clinical trials, so physicians involved in those, they're legally obliged to help with that process. Spontaneous reporters that we refer to, which is just where any healthcare professional or consumer contacts, the company, that's a voluntary reporting system, so we can ask them for additional information, they don't have to provide it, but we have to ask the questions anyway. So the information gets pulled together. It then goes, usually goes through a medical review, so we have kind of scientists pulling the data together. And then we have physicians reviewing the case, making sure it makes medical sense. And then depending on the seriousness of the case and other attributes, that case might have to be reported out to regulators worldwide.And a lot of the reports which are serious, have to be reported out within 15 days of what we call day zero, which is the first day anyone in the company became aware of the report. Parmvir: Mm-hmm. David: But to give you an idea, the large pharma companies are dealing with potentially tens of thousands of reports a week that are coming in on all of their products. So these are vast systems that are set up and they have to be set up to be able to meet all of the regulatory requirements in terms of timelines, for reporting. So the data's coming in, the expedited reports are going out in the format that the regulators require. We also have to pull together what we call aggregate reports. So these aggregated analyses of data over time for newer drugs, for example, those are submitted in Europe every six months. And then over time as the drug gets older, the gap between reports gets longer. And then also we're doing something, what we call signal section, which is where we are analyzing the data. And we're looking for trends in the data. Where we think we've got patterns we're starting to then look into researching those patterns a little bit more, you know, if we start to see, for example that I don't know that we are getting what appears to be a disproportionate number of nose bleeds, let's say, in a patient cohort, we would, you know, do background research on, well, you know, is there a plausible biological mechanism that we know about through the development of the drug? Was there stuff seen in the animal studies or even the human studies that might indicate that there's a, there's a root cause here.We'll look into confounding effects. Are all these patients on other drugs, which actually are likely causing that? And yeah, so kind of an appraisal is done: what's going on? Is it likely to be caused by something else? And if not, you know, we, keep on looking and those conversations then have to be shared with the regulatory authorities.And over time, what you'll see is the labeling of the product, the professional labeling which in Europe, including the UK, is the SMPC, the summary of product characteristics, which is a bit like the instruction manual for the product, which is available to healthcare professionals and the simplified version of that PIL those little leaflets you find inside of packs, those eventually get revised on an ongoing basis to accommodate the new knowledge that we are gaining on the side effect profile of the drug. So this is an ongoing process and it happens throughout the entire lifetime of the, of the drug. Parmvir: But yeah, so here's a subject that no one's talked about for a little while. COVID 19 David: mm-hmm Parmvir: [laughs] Obviously I know there's probably a collective groan from people listening right now, but it seems like a relevant subject, given the conversations around safety that people are having with regard to the vaccine. So do you know if there's been like a major uptick in these reports by individuals, of side effects from the vaccines, or do you take account of the fact that so many billions of people essentially at this point have received at least one shot of the vaccine versus how many reports you get coming in?David: Yeah. So this is one of the big challenges, and one of the things I should have said about drugs like vaccines is because they're given to such vast numbers of people, it becomes a particular challenge to differentiate between things which are being caused potentially by the vaccine and other things, which unfortunately are just bad luck of being a human being.And by that, I mean, so years ago when I was doing one of the academic courses we were being taught about the vast amounts of research that had to be done in terms of epidemiology before the HPV vaccines were released. So these vaccines were being released for use in teenage girls, and at the time it was felt that there was perhaps an insufficient understanding of the general health of that population, including things like what is the probability of a freak occurrence that a teenage girl is going to have a stroke or something like that? Things which we think of as of course, they're exceptionally rare, but they do happen.Parmvir: Mm-hmm David: and I'm talking about in untreated populations. Parmvir: Yep. David: But of course, you know, some of these patients are also on birth control and things like that, that also have other risk factors associated with them so my understanding is before the HPV vaccines were released, a huge amount of epidemiology research was done so that when the new vaccines were released, we knew that we would expect, and I'm just gonna make up a number here that, you know, one in 500,000 teenage girls would have, I don't know, some kind of fatal event which would just naturally occur, you know, even without them having the vaccine. And so that's similar for other vaccine rollouts as well. There has to be a good understanding of the background events of other things that, people will have happen to them, which have nothing to do with the medicine that you are giving.So, you know, that data is kept available and kept an eye on by the regulatory authorities and also the pharma companies. We don't have background rates for everything, so being prepared for what might come and then, you know, there perhaps isn't so much panic when the first case comes in of a patient that has one of these catastrophic events but if you start to see more than that, that's when you start to perhaps get more interested in: is this really being caused by the vaccine or the drug of interest. So, yeah, a lot of upfront work has to be done before you even put the drug out there. I mean, in terms of the COVID vaccines and the treatments, because of the high degree of public interest and scrutiny a lot of these drugs when they were first given and the vaccines were first given, so adverse events, side effects were tracked through post-authorization safety studies. So actually a lot of people, when they got their first doses, consented to have maybe a follow up call from an investigator who would ask them about various side effects that happened. So in addition to all of the natural spontaneous reporting that was coming in, there were very large cohorts of past study data coming in which is a robust way to look at these things. I know as well, there were legitimate questions about, you know, the COVID vaccines in particular were produced fairly quickly compared to the usual 10 to 15 years in development of, of a product. But you know, there are various reasons for this. So vaccines are perhaps one of the medicines where it's more possible to template out the product and therefore switch out components. But they still have a product which is similar to other products that have previously been used. But also, the COVID era in terms of vaccine development and treatment development was, in my opinion at least a completely unique event in terms of drug development so far. If you think of drug development as a kind of universe, or I'm gonna use some wonky analogies here, but let's say as galaxies, which have solar systems within them that have planets within them.So if you think of the galaxy of drug development you have all of these different stakeholders involved. You have the pharmaceutical companies and biotech companies and the service companies that support them, that's one area. You have the regulatory authorities but you have many other stakeholders.You have patients, of course they're the most important. For chronic diseases you might have patient advocacy groups. But also, you know, you guys are part of this universe as well, because you are the ones doing basic research, which is the foundation on which all, you know, all of this is, is ultimately built. So you have universities and other research organizations. You have the funding bodies that sit behind those that decide where the research money goes. And then out the other end of the process you have ethics committees that are involved in approving clinical trials. You have payers. So these are the organizations that ultimately pay for medicinal products in the UK, for example, that's the NHS. Parmvir: Yep. David: In the US, that would be insurance companies. Parmvir: Yeah. David: You have many other stakeholders. So you have obviously healthcare professionals at the end of the day, new drugs have to be woven into the fabric of medicine. And so you have to bring HCPs along with you. There are the learning bodies as well in relation to HCPs, the kind of professional bodies.So that's really at a kind of galaxy level, these are all the different solar systems. And then within them, if you look at the pharmaceutical biotechnology and service provider solar system, within those you have an incredibly complicated set of different skills departments, functions, you have the functions that are doing discovery.So these are the early days of, development where, you know, biologists and chemists are working out, you know, what are the new therapeutic targets we can look at? Then you have the clinical development division. You have the patent divisions, you have the regulatory affairs functions. You have the pharmacovigilance functions. You have the medical affairs functions, you have the medical information functions [Parmvir cackles]. There are, and I'm going to miss out many, many. You have the, the bio stats folks, you have the medical writers. And then of course you have the manufacturing, which is in itself a completely different, you know, specialized world.So yeah, you're dealing with a very complicated process with lots of things which are interlinked. But for me, if you think of all these things, like if you use layout or different compass, let's say, and I'm talking about the compass you use to check direction, not the ones you used to draw circles [Parmvir laughs] and if you scatter them all out they'll all be pointing at different directions. You know, all of these different entities have their own priorities. Because of course the industry as a whole is developing many different medicinal products for different reasons. I think when COVID came along, it was like drawing a magnet across the top of all those compasses and it got all the needles to point in the same direction.So you had governments who had a clear incentive to try and support the development of treatments. So you had governments putting up money, which was perhaps slightly unusual. They were putting money into basic research, such as the type of stuff that you guys do. They were putting money into diagnostics, which are critical for things like COVID.They were putting money into the development of vaccines and into treatments. And then of course, you know, you have the pharma companies where there was a scramble to try and develop something, to help humanity in its hour of need. You had the regulators with a lot of focus on them you know, and everyone watching their, every move and trying to ensure that you know, as many processes that often might take months, or perhaps even years were made as efficient as possible.Parmvir: Mm-hmm David: And it was a unique point in time because everyone was lined up with the same objective. So it meant, for example, that, you know, parts of the industry, which are normally a nine to five job, became a 24/7 job. Parmvir: Yeah. David: For a short period of time.And there was a huge amount of collaboration, which happened between the different stakeholder groups, you know regulatory authorities offered perhaps free scientific advice to companies that were developing this stuff. They met very regularly with companies that were in development. They gave a lot of advice as to what their expectations were when the data was received by them. They shortened some administrative pathways let's say which usually take a lot of time. They prioritized resource. So there's resource specifically waiting for this data to come in. And so, yeah, a lot of normal processes were adapted so that things could be done as efficiently as possible.And the outcome was that, you know, these drugs went through the entire process in a much more efficient way than would usually be encountered. I think another thing as well is with things like vaccines, the side effects that we anticipate to see, including the rare unusual ones ordinarily these manifest within, you know, days or weeks.It's not something that usually we anticipate things to occur years later. So there was that aspect too, but yeah, it was a, it was a unique time. Parmvir: Yeah. And actually this is a good throwback to Dr. Carina Rodriguez's podcast because she ran one of the clinical trials for the vaccine in children at USF where I work.David: Oh, fascinating. Parmvir: Yeah, so she talked about some of the things that you mentioned as well. David: I should say I was not involved sadly in any of the COVID vaccine development, but you know, it was fascinating to watch and actually to see my profession become a talking point in the news every day. Parmvir: Yes. David: It was very interesting to see all of this play out.Parmvir: Yeah. So actually, that's probably a good point to pause and ask you, what do you actually do? David: Okay. So [everyone laughs]. So as I've kind of indicated the process of pulling in adverse event data of coding it, which is the term we use for tidying up all of the data, putting it into a safety database, writing those narratives, getting the medical review, getting the important cases out the other end to the regulators, writing the reports, doing the signal section.These are very complicated processes and every company will develop them slightly differently. You know, small biotech companies, they might only have one product. It might only be approved in one or two countries. A top five pharma company will have hundreds of products authorized in many countries around the world. But all of these processes are put together in compliance with extremely strict regulations. Regulations that as I said exist in almost every country in the world and actually the regulations kind of cross over in the sense of, if you have a product that's authorized for marketing in the UK and the US, for example you know, the UK requires you to collect all the data and analyze it as does the US.They also require you to collect the data from each other's territories so companies are in the middle of the very complicated regulatory framework, which is a little bit different in each country, but fortunately is harmonized through some international bodies and international terminology. But building pharmacovigilance systems is complicated and it has to be done right. Firstly, for the obvious reason that we want to protect patients it's in no one's interest that that that patients are not protected. But also, you know, the penalties for not complying with these complex regulatory requirements are severe. And so my job really, as a, let's say senior leader within a pharmacovigilance department is to make sure that we build the right structures.And for these companies that we that we keep an eye out on all the areas, which are potential challenges and that companies are being compliant with the legislation to which we're all held. And so, so yeah, so building pharmacovigilance systems, I think is the simplest way I can describe it.Parmvir: It sounds pretty heavy and pretty complicated. David: Yeah. I mean, if you look at the larger pharma companies, if you add up all of the resource that they put into pharmacovigilance that they're legally required to put into pharmacovigilance, to service the needs of their products. A lot of things are outsourced these days, if you the count everything that comes from the outsourcing organizations as well, the big pharma companies have thousands of people like me involved in the processing and analysis of this data. So it is a big area, and that is all we do. You know, we are not involved in any other aspect of the drug. Not involved in the sales and marketing, for example, with the product, that's almost the complete opposite side of the company to us, all we do is you know, work in this very professionalized, very standardized discipline, which is pharmacovigilance. Parmvir: So David has a couple of questions. So first one should be relatively quick, which is that, is there a regulatory authority that is the gold standard? David: [David laughs] This is a very politically sensitive one.There are certainly some regulatory authorities who, particularly in some of the larger markets who are let's say more prominent. So examples would be the US FDA, the food and drug administration that is the drug regulatory authority for the United States. In the UK, we also have an extremely prominent regulator, the MHRA they're one of the oldest regulators, I believe in the world. So that's the UK medicines and healthcare products, regulatory agency. But you know, every country has its own regulator and whilst there are some who put themselves out there, perhaps as world leading regulators, there are just as many others that are doing the same important job for their countries. The European Union and European Economic Area has a slightly more complicated system because they have a coordinating regulatory authority, which is the European Medicines agency, the EMA, who many of you all have heard about in news reports, particularly during the COVID situation. But at a national level, you also have all of the national regulators who are working in tandem with the EMA. Parmvir: Okay. So this sounds quite different from, obviously it's very different from what you were doing during your PhD. David: Yes. Parmvir: He also wants to know, how did your PhD work, prepare you to do what you do now. David: If I could sum it up in one phrase, and this is a phrase which is overused, but I think in this case, it is really true: problem solving.Parmvir: Mm-hmm David: because it's interesting, you mentioned earlier that you and I we're almost engineers. Well, I went from becoming a physical engineer, at least in a lab environment to a process engineer. And, you know, I always used to think very naively when I was doing the basic research with you, I used to think, look, we are solving problems that no one knows the answer to. This must be the hardest job in the world. [Parmvir laughs] We're not solving manmade problems. Manmade problems must be so easy to solve. But no manmade problems [Parmvir laughs] are also particularly challenging. And when I say manmade problems, you know, I'm not talking about problems that someone is deliberately created, it's just, you know, logistical challenges, and just the challenges caused by working in, you know, different regulatory envionments with different sets of requirements and how to build processes that meet all of the requirements at the same time. And react to events, of course, because it might well be that you've had a product that has been ticking along nicely for a long time. And then suddenly there is a safety concern with the product. And if that safety concern is in the public domain, you will be deluged with reports in relation to that product called stimulated reporting. And you know, of course sometimes companies will be subject to class action lawsuits particularly in the US. So they might also receive large volumes of reports all in one go. All of those reports have to meet the same legal timelines, but now suddenly you've got 10,000 reports landed on your desk. Each one takes four hours to process and they're all due to the regulators in 15 days. So yeah, it is challenging working in a hyper regulated environment. Parmvir: Essentially these are problems that come about because we are humans. David: Exactly. Yeah. Parmvir: And we have to somehow live together. David: Yeah. Parmvir: So I had a couple of questions from my little sister and these might not be directly related to your work, but they are related to the fact that you work within an environment that involves clinical trials and patients and so on.And so Sukhy wants to know are side effects from drugs, usually the same for healthy people versus patients. David: This is a great question and cause me a little bit of head scratching. I think, I mean, the answer is it depends, I think by and large. Yes. But there will be some exceptions and those exceptions include things like some of the oncology treatments, because obviously there is an interaction often between the drug and the tumor, for example, so in a healthy person you can't emulate that because there is no tumor. So an example would be a phenomenon called tumorlysis syndrome which can only occur when there's a tumor to react to the particular drug. But by and large, yes, we extrapolate safety data from healthy individuals initially, which is why the earlier phases of studies are done often in healthy volunteers with some exceptions. But yeah. Then when we move on to phase two and then phase three, phase two and three are conducted in patients that have the indication of interest, I have the disease that we're trying to treat.Parmvir: So another question she had: how do you know people who are not healthy will be able to tolerate the drugs given that initially that they're tested on healthy people?David: So the first thing I would say is I'm not an expert in the design of clinical trials, but as I said, as you go through phase one which are the trials that are normally on healthy patients, you actually start out with a tiny, tiny dose. So you have an idea of dosing from your animal studies, but the data isn't always transferrable. But you take the maximum tolerable dose in animals, including in the most sensitive animals. And you then cut that by huge factor by perhaps 500 fold. Parmvir: Right. David: So you start out with a tiny amount and then you escalate up the doses to see how the patients are tolerating the drug, not the patients subject, I should say. So these are healthy volunteers usually. Parmvir: Yep. David: So that's phase one, but yeah, then of course, when you go into phase two, you're dealing with a different patient population. I don't know exactly how that's always done, but of course, you know, trials are put together by experts in the field. And they involve, you clinicians whose expertise is this particular area of medicine.Parmvir: Yeah. David: And of course it's not just the physicians at the pharmaceutical company and the biopharma company and the scientists, I should say as well. Also, this stuff is going to regulatory authorities, it's going to ethics committees, all of whom will have their own areas of expertise. So, you know, protocols are designed around the patient and to ensure the patients are not put at unnecessary risk.Parmvir: Ah, sometimes David sends me one of those questions that really makes me giggle. And this is if regulations are so important and onerous, how do I start my own biotech in the garage? David: [David laughs] Well, it's interesting, you know, companies don't necessarily have to be that big themselves to get started, but what they will need is a lot of help.Parmvir: Yeah. David: So what you'll see these days is you know, new biotechs starting up. But they rely very heavily on outsourcing. So they will partner with service providers with contract research organizations, with contract manufacturing organizations, all sorts of other parties that have the expertise that perhaps they aren't able to pull together themselves.But yeah, there are some companies out there, particularly smaller companies in earlier development that are, you know, pretty small might have 20 people in the company. Parmvir: Yeah. David: But they will need to rely on the help of many others, because going back to the kind of universe description that I gave, you know, there are so many specialized areas that you need to have covered in order to pull together everything you need, both to run a clinical trial. and also to submit a marketing authorization application. And then also keep your product compliant with all of the legal requirements that are out there.Parmvir: It's a lot.David: It is a lot, and you know this is why drug development is so costly because it needs a truly vast number of specialists involved. And, you know, quite a lot of physicians as well. And also, you know, most drugs that enter drug development don't make it all the way through the other end, so the end costs of medicinal products also have to cover the cost of the drugs that didn't make it.And plus companies only have a certain period of exclusivity before their drug becomes generic, i.e., other companies can start making it. Parmvir: So this is purely from a personal perspective, from your point of view: what do you think about the fact that obviously you have these companies who have put so much money developing these things, which were designed to treat a global pandemic. And yet we found that for example, like entire continents, like Africa still don't have a lot of people vaccinated against COVID 19, and those companies will refuse to open up the patents to allow them to be able to get people to stay healthy. David: Yeah, it's an area that really I'm not really sufficiently qualified to talk on. And I'm not just saying that, you know, through not wanting to put my foot in my mouth, but particularly with some of the vaccine technologies that were used, they were not simple medicines to manufacture. So not simple to manufacture, not simple to store, not simple to distribute. And sometimes I guess, it is perhaps a legitimate concern of a company that if other companies start making their same drug to a lower quality, that can have ramifications elsewhere. Now I'm not saying that that was the reason behind some of what you mentioned. Now there was a vaccine that was developed the UK vaccine which was specifically developed from the outset to be made available in developing world countries, let's say, and specifically to be made available at cost. And even the way that product was designed, it can be manufactured and stored at fridge temperature Parmvir: mm-hmm, which is a big deal. David: Exactly. It is a big deal, you know, those are all very important components to consider. A vaccine that could be used in those environments. But even, I remember because I vacuumed up all of the documentaries I think on television, Netflix, everywhere else about all of the challenges that were being faced. And, you know, there were even things that you just wouldn't think about, which was, you know, because the mRNA vaccines had to be stored at -80 [degrees Celsius], there wasn't enough minus 80 freezers in the developed countries, let alone figuring out how to develop and ship these to other countries with different climatic conditions.And so you even had the manufacturers of that type of equipment, having to up their game and suddenly churn out much more equipment than they previously had. So, yeah, there's no simple answer. I mean, historically there've been other challenges in the past with other types of drugs, such as the HIV medications. In the end access to those drugs was resolved through very careful dialogue between companies, regulators others. Access issues, I believe to those drugs, and again, this is just basically what I see on documentaries and other things; where are access problems these days, they're not in relation to the drug supply chain they're in relation to other things like people not wanting to come forward and receive treatment because of the stigma associated with things like that.Parmvir: So in short, do you enjoy your work? David: I do. I mean, I can honestly say that in my work every day is different. I'm very privileged in my job to support a number of different companies that are developing different products with a very wide variety of indications. And also, you know, just when you think you've seen it all worked with a wide variety of medicinal products, suddenly something completely new will come along. For example, we are now on the precipice of many commercial gene therapies coming out. Parmvir: Ooh. David: And you know, those products have some different considerations. Perhaps some of these interventions are irreversible Parmvir: mm-hmm.David: So, you know, what happens if patients do start developing something rare and unexpected. You have patients surviving a lot longer than was originally envisaged so, you know, are there other things which come about you know, as a result of the underlying disease that just no one had ever seen before. And yeah, many other types of technologies and the regulations are always having to evolve to take into account of these new therapies and the challenges associated with them.Parmvir: Well, it sounds like you will continue to live in interesting times. David: Yeah. I don't think I'm going anywhere anytime soon . Parmvir: Well, thank you so much for your time today, David. That was fantastic. And yeah, as I say, we kind of thought of you as soon as we started thinking about the safety surrounding things like COVID vaccines and knew that was your jam.So yes, we very much appreciate your time today. David: Okay. Thank you very much. [musical interlude]David: So I mentioned earlier that at an early point in my PhD, I switched to studying vascular endothelial cells that were harvested from pigs. So essentially these were pigs that were being slaughtered for the meat industry. And so I had to look through a phone book and identify an abattoir that I could go to and get the tissue that I needed to do my experiments so obviously this all had to start somewhere. So I put in a call to an abattoir in deepest, darkest Essex. And I gingerly made my way on the train to this place, which of course was in the middle of rural nowhere. And unfortunately the first day that I picked to go, it was snowing. Now we don't get vast amounts of snow in Southern England, but this was a decent sprinkling of snow. So I arrived in this quiet rural destination and I walked across various fields. I think I'd perhaps just got GPS on my phone, but it was very early days. And I was lost in fields of white in no time at all. So I ended up putting in a call to, the guys, to, come and pick me up, which they very kindly did. So then, you know, at that time I really didn't know what a coronary artery looked like so what I decided to do for that first trip was I just collected the fresh hearts that they were able to bring out the processing facility. So these were kind of warm pig hearts, freshly harvested from animals. I think I had three hearts or something like that. And so I had a large polystyrene box with me with some ice in it. And I think they were kind enough to give me the ice, as I put these hearts inside bags and put them in the box and then started making my way back to London. And of course, you know, this being a cold day, the heating was on, on the train, and so as I was sat on the train, in fact, I think it was when I got onto the tube, I suddenly became horrified that my polystyrene box was starting to leak water. And of course I knew, but no one else knew on the tube that within that water were bags, perhaps not secured, very tightly containing hearts and containing probably a fair amount of blood.And I suddenly started sweating that this puddle that was starting to pull around my polystyrene box on the floor of the tube would suddenly start to go pink and then red. And then before I knew it, I would be in serious trouble. So it was just one of those situations where the tube journey seemed to get longer and longer, and I was sweating more and more and then it got to the point where I felt that I couldn't wait any longer, so I kind of dashed outta the tube at the next station went up what was perhaps one of the longest escalators on the underground and managed to just get out the other side before I caused perhaps a fake terrorist incident or something like that. I was trying to think about how I would explain that I'd got three hearts in my polystyrene box and a set of scalpels bearing in mind that pig's hearts are very similar size to human hearts as well. So, yes, I managed just about to get to the lab. I clearly looked quite distressed, I suppose when I got back to the lab. So I started telling this story to my PhD supervisor, Dennis, and uh a retired professor that had come into the department, Don. And before too long, the two of them were crying with laughter at my story.So, um, so yeah, so that was my very first trip and yes, never, never forgotten.[musical outro]David: Our lab, when we first joined, it was quite old and a bit dog eared. And there was one particular chair in the office, which was, I mean, it was like a typical office swivel chair, but it had definitely seen better days and it was extremely uncomfortable. And when we had lab meetings, no one wanted to sit on this chair. And so Parmvir and I nicknamed it, Beelzebub's stool.

Naši vědci a projekt SIRIUS, 2. část: Pilíře výzkumu (4:22) – Historie: Založení osady Vánoce (18:34) – Knihovnička: Vesmírníček (23:36) – Kanibalové, 1. část (27:49)Všechny díly podcastu Planetárium můžete pohodlně poslouchat v mobilní aplikaci mujRozhlas pro Android a iOS nebo na webu mujRozhlas.cz.

L'approfondimento settimanale di Radio 24 dedicato al mondo dei trasporti e della logistica, un settore che rappresenta in Italia la terza filiera per fatturato (dopo l'agroalimentare e l'edilizia) e che vale il 12% del Pil nazionale, oltre a rappresentare la cerniera di collegamento tra il mondo produttivo e il consumatore finale. L'efficienza del sistema di trasporto, sia di passeggeri sia di merci, ha sempre avuto un ruolo determinante nello sviluppo economico e sociale di un popolo. E la capacità di muovere gli atomi -unita oggi a quella di spostare bit- può ancora cambiare le sorti di una nazione. La trasmissione è realizzata in collaborazione con il Comitato Centrale dell'Albo degli Autotrasportatori (Ministero delle infrastrutture e della mobilità sostenibili)

Guest host Troy Swanson chats with Dr. Alison J. Head, founder and director of Project Information Literacy, about PIL’s early days, PIL’s unique place in the information literacy research field, the importance of student and information agency, and what’s next for the PIL group! Read the transcript! Alison J. Head, Ph.D. is an information scientist and … Continue reading 230: Project Information Literacy, with Dr. Alison J. Head

Nessuna frenata, solo uno stop alla corsa del dato annuo. Nelle stime preliminari Istat l indice nazionale dei prezzi al consumo per l'intera collettività (Nic), al lordo dei tabacchi, registra un aumento dello 0,5% su base mensile e dell'11,8% su base annua (come nel mese precedente). Su base mensile si tratta così del settimo aumento consecutivo e nel confronto annuo non vi è alcun arretramento, per un dato (11,8%) che in Italia non si vedeva dal lontano 1984. "L'inflazione acquisita per il 2022 - scrive l'Istat - è pari a +8,1% per l'indice generale e a +3,7% per la componente di fondo". Di contro, sempre l'istituto di ricerca, conferma le stime di ottobre per quanto riguarda il prodotto interno lordo: nel terzo trimestre del 2022 l'economia italiana è cresciuta dello 0,5% rispetto ai tre mesi precedenti e del 2,6% rispetto allo stesso periodo del 2021, con una crescita acquisita per l'intero 2022 pari al 3,9%. Secondo Istat 'tirano' consumi e turismo, giù l'industria. D'accordo l'Ufficio Studi di Confcommercio, secondo il quale, in questa fase, il turismo è una "diga contro la recessione. Ne parliamo proprio il direttore dell'Ufficio studi Confcommercio, Mariano Bella. Mezzo milioni di poveri al sud a causa del caro energia. 1,2 milioni di giovani hanno lasciato il Mezzogiorno Oltre 760.000 potenziali nuovi poveri per lo shock energetico, di cui mezzo milione al Sud. È lo scenario delineato nel Rapporto Svimez 2022, giunto alla sua 49esima edizione, presentato, lunedì 28 novembre, alla Camera dei Deputati. Il mezzogiorno rischia la recessione. Nel 2023 il PIL meridionale si contrarrebbe fino a -0,4%, mentre quello del Centro-Nord, pur rimanendo positivo a +0,8%, segnerebbe un forte rallentamento rispetto al 2022. Il dato medio italiano dovrebbe attestarsi invece intorno al +0,5%. Il 2024 dovrebbe essere un anno di ripresa sulla scia del generale miglioramento della congiuntura internazionale, unitamente alla continuazione del rientro dall'inflazione. Si stima che il Pil aumenti nel 2024 dell'1,5% a livello nazionale, per effetto del +1,7% nel Centro-Nord e dello +0,9% al Sud. Un altro elemento che emerge dall indagine riguarda l ambito della formazione, e in particolare l università. Secondo Svimez, infatti, nel 2041 il Mezzogiorno perderà il 27% degli iscritti, il Centro Nord circa il 20%. Negli ultimi vent'anni circa 1,2 milioni di giovani ha lasciato il Mezzogiorno. Uno su 4 è laureato. Ne parliamo con Luca Bianchi, direttore dello Svimez. Bruxelles. Nuovo regolamento sul packaging. L'industria Ue dell'imballaggio boccia il piano Bruxelles ha presentato oggi la proposta di regolamentosul packaging e punta sul riuso e il 'vuoto a rendere' per bottiglie di plastica e lattine in alluminio. L'obiettivo è ridurre i rifiuti di imballaggio del 15% pro-capite per ogni Paese entro il 2040. Secondo la proposta di regolamento, entro il 2030 il 20% delle vendite di bevande take-away dovrà essere servito in imballaggi riutilizzabili o usando i contenitori dei clienti, per arrivare all'80% nel 2040. La proposta regolamento da tempo è al centro di allarmi in alcuni paesi e, in particolare, in Italia paese leader nel settore del riciclo perché si preferirebbe il riuso dei materiali al riciclo. Tra le contestazioni la scelta Ue di procedere con un regolamento, con il quale vengono rese immediatamente applicabili le norme che, in ogni caso, saranno oggetto di negoziato tra Consiglio e Parlamento Ue. L'industria dell'imballaggio Ue boccia il piano di Bruxelles. "La proposta rischia di andare contro gli obiettivi del Green Deal, riportando indietro le lancette dell'orologio del riciclo e compromettendo la funzionalità degli imballaggi nel proteggere i prodotti e prevenire i rifiuti", evidenzia l'organizzazione di categoria, Europen, che tra i suoi membri conta anche Ferrero. Ne parliamo con Armido Marana, Vice presidente di Confindustria Vicenza con Delega alla Sostenibilità.

Città d'arte campioni nella creazione di ricchezza turistica e centinaia di comuni si rivelano dei top performer del Pil grazie all'industria dell'ospitalità. Al primo posto della classifica ecco Roma con circa 7,6 miliardi di euro seguita da Milano con circa 3,5 miliardi, Venezia che supera di poco i 3 miliardi e Firenze con più di 2,8 miliardi. Non mancano poi le sorprese come San Michele al Tagliamento che grazie alla frazione Bibione riesce a battere la rinomata costiera amalfitana, Cavallino-Treporti supera Taormina e Chioggia lascia al tappeto Ischia. Sono questi i sorprendenti comuni campioni del valore aggiunto generato dalle attività turistiche. È quanto emerge dallo studio «La ricchezza dei comuni turistici - Ranking secondo la creazione di valore aggiunto», preparato da Sociometrica elaborando i dati Istat. Il focus dello studio è sui primi 500 comuni per presenze turistiche, dove si concentra l'83% del totale degli ospiti.Oltre alla classifica dei comuni italiani per Pil dal turismo, Sociometrica ha anche stimato l'andamento del 2022 che vede l'avvicinarsi dei flussi ai livelli del 2019. In termini di presenze complessivamente lo studio stima per quest'anno 389,4 milioni di presenze contro i 436,7 milioni del 2019 con un gap del 10,8%. In termini di valore aggiunto generato dalle presenze turistiche nel 2022 si superano gli 89,1 miliardi di euro contro i 99,9 miliardi del 2019. Quindi un settore in forte ripresa che si avvicina ai livelli pre pandemia anche se, per riuscire a raggiungere i livelli del 2019, sarà necessario fare i conti con il caro energia, che potrebbe mettere in pericolo la sostenibilità di tante attività, oltre che la diminuzione della domanda a causa dei prezzi in forte salita. E la questione occupazionale, con alcune professioni difficili da reperire sul mercato. Ne parliamo con Antonio Preiti, economista e direttore di Sociometrica.

In this episode, we recap and analyze Episode 16, the final episode of It's Okay to Not Be Okay, the hit K Drama on Netflix. In this episode, the story is Find the Real, Real Faces by Meun Young. Sang Tae convinces Meun Young to publish her final book, which is about three friends (an emotionless princess, a boxed man, and a masked man) whose faces were stolen by an evil shadow witch. After a long journey and meeting many characters, the friends realize that what the shadow witch had stolen from them was not their real, real faces but their courage to find happiness.This episode was ultimately about Gang Tae, Sang Tae and Meun Young finding the courage to be happy. Gang Tae learned to be vulnerable, to ask for help, to love and be loved, and to believe that he wasn't born to take care of Sang Tae because Moon Gang Tae belongs to Moon Gang Tae. Meun Young was able to shed the narrative that she is an empty can, unable to care about others' feelings. Meun Young came to care about the brothers, rejoin the community, love, be loved, and write again. Sang Tae was able to overcome his trauma, paint over the murderous butterfly and paint his own butterflies, and leave Gang Tae to pursue a career as an illustrator.This episode also revisited the stories of some of the patients at the hospital, including A-reum and Jung-tae, who are finally together; the assemblyman's song, Kwon Ki-do, who is studying for the national civil service exam; Pil won, who has a new pair of shoes and the courage to leave the hospital for good; and Eun-ja, who has accepted her daughter's death and has opened up her own restaurant.Even the second and third couples look like they're going to make it. The publisher is opening up his new office in Seongjin City to be closer to Ju-ri, and Jae-soo appears to be getting closer to the art director.At the end of the episode, Joanna, Jen and Sung Hee reveal the show they are going to recap and analyze in Season 3 of K Drama Chat – Mr. Sunshine! We wanted to do a historical show and decided Mr. Sunshine had a lot to discuss, including Korea during the Japanese occupation, how Japan and the US fought over Korea, the rebellion against the Japanese, the role of women during that period of time, gender identity, and Korean language.We will have a few in between episodes before we start talking about Mr. Sunshine, so keep listening and start watching Mr. Sunshine!

#519 largando labaredas pelas ventas com PiL, gonzaguinha, hawkwind, grace jones, marilyn monroe, gabriel muzak... chega+!

A tribute to Mimi Parker of Low and Keith Levene of early PIL and founder member of The Clash.

(Hello, Virgin Records?)Every mile away from LondonIs a mile away from where he needed to be.Subsequent Chronological Milestones:  PIL (The Good Years) 79 - 85 / Killing Joke - Extremities / Ministry - In A Cage - 12 Weeks of insanityPig Face – 600 degrees of separation - Budgie has the baseball cap!  NIN'S Head like a Hole and Wish / Murder Inc and still out there!  Street lives…. (Rail ‘em in and Regiment)Setlists? Who uses a set-list?PIL had a looseness that belied their commitmentNew York Gig discussion – what do we start with?3000 people Martin onstage and John and Keith have left the buildingKeith Levine wanted only green lighting – John Lydon wanted to be back in the hotel.  Strippers and Homework in the Dressing roomNo rehearsals - like an old-style jazz bandHow we gonna end? - Smoke signals!  Serving time in North of England Labour clubsBackstage Beer in the Pot, or is it?Satisfying Sayonaras...Leaving The Mynd and its Mellotron  Martin goes to LondonMelody Maker ad – Drummer required for well-known singer.“I'm really good – can I audition today?”Wait – we just Set the drummer on fire!Serendipitous Savings…Curator of Chicago's Post Punk Museum  Dressing room sign from American BandstandMartin's Mickey Mouse watchWhiskey and MeditationScintillating Scent of Success …Speed, Alcohol plus Scratch and Sniff Banana postcards!No. 3 = Smell of MoneyNo. 4 = Sweaty Boys in a Mosh PitNo. 5 = Paper cup from a John Peel sessionHappy Anniversaries and Memories  No diary for Lol the ExistentialistTwo Sides to Every Story…Theory begets RealityMartin = 90% Comedian; 10% HistorianOwning our past - 1st Class or 2nd Class?  Crystal clear recollections ofJohnny Rotten, Jazz Coleman and Al JourgensenSuperior Performers…A bus-full of Junkies and Chlorine Gas  Tolerance and Respect for Crazy Charismatic people  A Rare and Undefinable BreedMartin - The MonarchBudgie - The DukeLol - The EmperorRead it in Books.We're blessed and grateful to be hereThree drummers and a Practice padWe belong togetherLike Three Peas in a PodDedicated to the Memory of Jeff Ward (November 18, 1962 – March 19, 1993) and William ‘Bill' Fredrick Rieflin II (September 30, 1960 – March 24, 2020)CONNECT WITH US:Curious Creatures:Website: https://curiouscreaturespodcast.comFacebook: @CuriousCreaturesOfficialTwitter: @curecreaturesInstagram: @CuriousCreaturesOfficialLol Tolhurst: Website: https://loltolhurst.comFacebook: @officialloltolhurst Twitter: @LolTolhurst Instagram: @lol.tolhurst Budgie: Facebook: @budgieofficial Twitter: @TuWhit2whooInstagram: @budgie646 Curious Creatures is a partner of the Double Elvis podcast network. For more of the best music storytelling follow @DoubleElvis on Instagram or search Double Elvis in your podcast app.

November of '79 is yet another month so big it has to be split in two. Join the lads for lively discussions around albums from the likes of Boomtown Rats, PiL, Marianne Faithfull and Adam and the Ants. Listen to the full playlist on Spotify: https://spoti.fi/3DI8IvC Email us at deepdives.deepcuts@gmail.com.

Le bollette del gas scendono: per i consumi di ottobre, le famiglie che sono ancora nel mercato tutelato (un terzo del totale) pagheranno il 12,9% in meno rispetto alle tariffe del terzo trimestre (luglio-settembre). Lo ha annunciato ieri Arera, l'agenzia pubblica che fissa i prezzi dell'energia. Il calo dei prezzi è dovuto alla riduzione della domanda sul mercato: gli stoccaggi europei sono stati riempiti e il riscaldamento non è ancora partito, complice un autunno davvero mite. Tuttavia il presidente di Arera, Stefano Besseghini, spegne il momentaneo entusiasmo dicendo che le bollette resteranno comunque salate rispetto al passato, e che fra novembre e gennaio risaliranno a causa della riaccensione degli impianti di riscaldamento. Ne parliamo con Stefano Saglia, Componente del collegio di Arera, Autorità di Regolazione Energia Reti e Ambiente.Nadef: oggi disco verde Cdm, poi dl bollette di 5-6 mld Oggi il disco verde alla Nadef e alla Relazione sull'aggiustamento di bilancio da trasmettere al Parlamento, poi a lavoro sul dl bollette quater, che arriverà subito dopo il via libera delle Camere alla Relazione che verrà definita e votata oggi a Palazzo Chigi . La roadmap del governo è questa, mentre si quantificano le risorse da mettere nel prossimo decreto per fronteggiare l'aumento delle bollette e il caro vita. Che dovrebbe ammontare sui "5-6 miliardi", consentendo di "estendere fino a fine anno le misure messe in campo dal governo Draghi, a partire dal credito d'imposta da prorogare". In generale saranno almeno 21 miliardi di risorse in deficit, oltre 15 miliardi per tutelare le famiglie e le imprese dall'emergenza energia. Nella Nadef, che l'esecutivo ha aggiornato con il quadro programmatico (il governo Draghi aveva fornito solo il tendenziale, senza gli effetti delle politiche economiche), il Pil 2023 verrebbe confermato al +0,6% (lo stesso dato indicato dal precedente governo). Una stima dunque cauta, nonostante la crescita superiore alle attese (+0,5%) del terzo trimestre di quest'anno. Per quanto riguarda invece l'indebitamento netto l'asticella verrebbe portata al 4,5% del Pil: considerato che la stima tendenziale è al 3,4% (ma non è escluso che anche questo dato possa essere rivisto), si aprirebbe uno spazio per il prossimo anno di oltre 21 miliardi. Durante il Cdm si parlerà anche di possibili modifiche al superbonus 110% e al reddito di cittadinanza ma anche di un possibile provvedimento sulle trivelle. Approfondiamo il tema con Gianni Trovati de Il Sole 24 Ore.

Lunedì 31 ottobre scorso è arrivata la comunicazione ufficiale del Mef sulla cessazione dell'esclusiva concessa a Certares, Air France-Klm e Delta per la cessione del controllo di Ita. Potrebbe quindi tornare in scena la cordata tra Msc-Lufthansa che aveva partecipato alla gara la scorsa estate, e Indigo Partners che aveva manifestato interesse lo scorso marzo. Intanto c'è attesa per l'8 novembre, giorno per il quale è in calendario l'assemblea dei soci di Ita che darà il via libera all'aumento di capitale da 400 milioni. Si tratta della seconda tranche del finanziamento complessivo da 1,35 miliardi di euro già autorizzato dall'Ue e suddiviso in tre tranche: 700 milioni per il 2021, 400 per il 2022 e 250 per il 2023. Nell'odg di quel giorno è previsto anche la revoca dell'incarico di presidente ad Alfredo Altavilla. Infine da indiscrezioni nell'assemblea del prossimo 8 novembre all'ordine del giorno ci sarebbe il cambiamento dello statuto della compagnia per la revisione del numero minimo di consiglieri, che da sette passerebbero a cinque per iniziare ad allineare il cda verso la privatizzazione. Ne parliamo con Giorgio Pogliotti de il Sole 24 Ore. Indice Cosulich. Furto del carico per la nave bloccata a Mariupol. Questa mattina sono salpate sette navi cariche di prodotti agricoli dai porti dell'Ucraina nell'ambito dell'accordo sul grano firmato lo scorso 22 luglio a Istanbul. È la conseguenza del ritorno della Russia nell'accordo di quest'estate dopo una sospensione di quattro giorni. Le navi sono state caricate con 290mila tonnellate di prodotti alimentari e sono dirette verso paesi europei e asiatici. Rimane però bloccata la nave del nostro Augusto Cosulich che negli scorsi giorni ha addirittura subito un furto al proprio cargo di 14mila tonnellate di bramme. Nel frattempo un pool di istituti composto da Crédit Agricole Italia, nel ruolo di Arranger, Lender e Banca Agente, e UniCredit, Cdp, Banco Bpm nei ruoli di Arranger e Lender, ha erogato un finanziamento di 29,5 milioni di euro, assistito dalla Garanzia Sace, a Fratelli Cosulich per la costruzione di una nave gasiera. Approfondiamo il tema con Augusto Cosulich, l'agente marittimo genovese, presidente e amministratore delegato della "Fratelli Cosulich". BoE: tassi a top da 2008, attesa recessione "per periodo prolungato" La Bank of England prevede "un outlook molto problematico per l'economia britannica, con una recessione per un periodo prolungato e l'inflazione a livelli elevati sopra il 10% nel breve termine". Questo anche a causa della contrazione dei redditi reali a causa dell'aumento dei costi dell'energia globale, cosa che ha un impatto negativo sui consumi e sulla spesa delle famiglie. La Banca centrale britannica ha alzato i tassi di interesse di 75 punti base, il rialzo maggiore dal 1989, portandoli dal 2,25% al 3%, il livello più alto da novembre 2008. In particolare, come si legge nel documento diffuso al termine della riunione della Monetary Policy Committee (Mpc), il Pil del Regno Unito e' atteso in calo nel 2023 (-1,9% a fine anno) e nel primo semestre 2024, per chiudere l'anno a -0,1% e risalire a +0,7% a fine 2025. La Boe prevede una fase "problematica" protratta, evocando la recessione più lunga della storia recente del Paese fin dagli anni '20 - ossia da quando si registrano i dati sul Pil - sebbene non la più pesante in termini di percentuali. Giorgia Scaturro de Il Sole 24 Ore.